

[19]	INTELLECTUAL PROPERTY PHILIPPINES		
[12]	INVENTION PUBLICATION		
[11]	Publication Number:	12015500499	Document Code: B1
[22]	Publication Date:	27/4/2015	
[21]	Application Number:	12015500499	Document Code: A
[22]	Date Filed:	9/3/2015	
[54]	Title:	RECOMBINANT MEASLES VIRUS EXPRESSING CHIKUNGUNYA VIRUS POLYPEPTIDES AND THEIR APPLICATIONS	
[71]	Applicant(s):	CENTRE NAT RECH SCIENT PASTEUR INSTITUT THEMIS BIOSCIENCE GMBH	
[72]	Inventor(s):	TANGY FREDERIC BRANDLER SAMANTHA DESPRES PHILIPPE HABEL ANDRE	
[30]	Priority Data:	27/9/2012 EP20120306176	
[51]	International Class 8:	A61K 39/00 20060101AFI20180723BHPH; A61K 39/12 20060101ALI20180723BHPH; A61K 39/295 20060101ALI20180723BHPH; C07K 14/18 20060101ALI20180723BHPH; C12N 15/86 20060101ALI20180723BHPH; C12N 7/04 20060101ALI20180723BHPH;	
[57]	Abstract:	The invention relates to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration. The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.	

The organization of the genome of measles viruses and their replication and transcription process have been fully identified in the prior art and are especially disclosed in Horikami S.M. and Moyer S.A. (Curr. Top. Microbiol. Immunol. (1995) 191, 35-50 or in Combredet C. et al (Journal of Virology, Nov 2003, p11546-11554) for the Schwarz vaccination strain of the virus or for broadly considered negative-sense RNA viruses, in Neumann G. et al (Journal of General Virology (2002) 83, 2635-2662).

The "rule of six" is expressed in the fact that the total number of nucleotides present in a nucleic acid representing the MV(+) strand RNA genome or in nucleic acid constructs comprising same is a multiple of six. The "rule of six" has been acknowledged in the state of the art as a requirement regarding the total number of nucleotides in the genome of the measles virus, which enables efficient or optimized replication of the MV genomic RNA. In the embodiments of the present invention defining a nucleic acid construct that meets the rule of six, said rule applies to the nucleic acid construct specifying the cDNA encoding the full-length MV (+) strand RNA genome. In this regard the rule of six applies individually to the cDNA encoding the nucleotide sequence of the full-length infectious antigenomic (+) RNA strand of the measles virus possibly but not necessarily to the polynucleotide cloned into said cDNA and encoding one or more protein(s) of the CHIKV.

According to a particular aspect of the invention, the nucleic acid construct comprises the following gene transcription units encompassing from 5' to 3':

- (a) a polynucleotide encoding the N protein of a MV,
- (b) a polynucleotide encoding the P protein of a MV,
- (c) the polynucleotide encoding at least one CHIKV structural protein,
- (d) a polynucleotide encoding the M protein of a MV,
- (e) a polynucleotide encoding the F protein of a MV,
- (f) a polynucleotide encoding the H protein of a MV, and
- (g) a polynucleotide encoding the L protein of a MV,

said polynucleotides and nucleic acid construct being operably linked and under the control of viral replication and transcription regulatory sequences such as MV leader and trailer sequences.

The expressions "N protein", "P protein", "M protein", "F protein", "H protein" and "L protein" refer respectively to the nucleoprotein (N), the phosphoprotein (P), the matrix protein (M), the fusion protein (F), the hemagglutinin protein (H) and the RNA polymerase large protein (L) of a Measles virus. These components have been identified in the prior art and are especially disclosed in Fields, Virology (Knipe & Howley, 2001).

In a preferred embodiment of the invention, the cDNA molecule encoding the full-length, infectious antigenomic (+)RNA strand of a measles virus is characteristic of or is obtained from an attenuated strain of MV.

An "attenuated strain" of measles virus is defined as a strain that is avirulent or less virulent than the parent strain in the same host, while maintaining immunogenicity and possibly adjuvanticity when administered in a host i.e., preserving immunodominant T and B cell epitopes and possibly the adjuvanticity such as the induction of T cell costimulatory proteins or the cytokine IL-12.

An attenuated strain of a Measles virus accordingly refers to a strain which has been serially passaged on selected cells and, possibly, adapted to other cells to produce seed strains suitable for the preparation of vaccine strains, harboring a stable genome which would not allow reversion to pathogenicity nor integration in host chromosomes. As a particular "attenuated strain", an approved strain for a vaccine is an attenuated strain suitable for the invention when it meets the criteria defined by the FDA (US Food and Drug Administration) i.e., it meets safety, efficacy, quality and reproducibility criteria, after rigorous reviews of laboratory and clinical data (www.fda.gov/cber/vaccine/vacappr.htm).

Particular strains that can be used to implement the present invention and especially to derive the MV cDNA of the nucleic acid construct are the Schwarz MV strain, the Zagreb strain, the AIK-C strain and the Moraten strain. All these strains have been described in the prior art and access to them is provided in particular as commercial vaccines.

According to a particular embodiment of the invention, the cDNA molecule is placed under the control of heterologous expression control sequences.

The insertion of such a control for the expression of the cDNA, is favorable when the expression of this cDNA is sought in cell types which do not enable full transcription of the cDNA with its native control sequences.

According to a particular embodiment of the invention, the heterologous expression control sequence comprises the T7 promoter and T7 terminator sequences. These sequences are respectively located 5' and 3' of the coding sequence for the full length antigenomic (+)RNA strand of MV and from the adjacent sequences around this coding sequence.

In a particular embodiment of the invention, the cDNA molecule, which is defined hereabove is modified i.e., comprises additional nucleotide sequences or motifs.

In a preferred embodiment, the cDNA molecule of the invention further comprises, at its 5'-end, adjacent to the first nucleotide of the nucleotide sequence encoding the full-length antigenomic (+)RNA strand of the MV approved vaccine strain, a GGG motif followed by a hammerhead ribozyme sequence and which comprises, at its 3'-end, adjacent to the last nucleotide of said nucleotide sequence encoding the full length anti-genomic (+)RNA strand, the sequence of a ribozyme. The Hepatitis delta virus ribozyme (δ) is appropriate to carry out the invention.

The GGG motif placed at the 5' end, adjacent to the first nucleotide of the above coding sequence improves the efficiency of the transcription of said cDNA coding sequence. As a requirement for the proper assembly of measles virus particles is the fact that the cDNA encoding the antigenomic (+)RNA complies with the rule of six, when the GGG motif is added, a ribozyme is also added at the 5' end of the coding sequence of the cDNA, 3' from the GGG motif, in order to enable cleavage of the transcript at the first coding nucleotide of the full-length antigenomic (+)RNA strand of MV.

In a particular embodiment of the invention, in order to prepare the nucleic acid construct of the invention, the preparation of a cDNA molecule encoding the full-

length antigenomic (+) RNA of a measles virus disclosed in the prior art is achieved by known methods. Said cDNA provides especially the genome vector when it is inserted in a vector such as a plasmid.

- 5 A particular cDNA molecule suitable for the preparation of the nucleic acid construct of the invention is the one obtained using the Schwarz strain of measles virus. Accordingly, the cDNA used within the present invention may be obtained as disclosed in WO2004/000876 or may be obtained from plasmid pTM-MVSchw deposited by Institut Pasteur at the CNCM under No I-2889 on June 12, 2002, the
10 sequence of which is disclosed in WO2004/000876 incorporated herein by reference. The plasmid pTM-MVSchw has been obtained from a Bluescript plasmid and comprises the polynucleotide coding for the full-length measles virus (+) RNA strand of the Schwarz strain placed under the control of the promoter of the T7 RNA polymerase. It has 18967 nucleotides and a sequence represented as SEQ ID NO: 1.
15 cDNA molecules (also designated cDNA of the measles virus or MV cDNA for convenience) from other MV strains may be similarly obtained starting from the nucleic acid purified from viral particles of attenuated MV such as those described herein.
- 20 The nucleic acid construct of the invention is suitable and intended for the preparation of recombinant infectious replicative measles - Chikungunya virus (MV-CHIKV) and accordingly said nucleic acid construct is intended for insertion in a transfer genome vector that as a result comprises the cDNA molecule of the measles virus, especially of the Schwarz strain, for the production of said MV-CHIKV virus and
25 yield of CHIKV structural protein(s), in particular CHIKV VLPs. The pTM-MVSchw plasmid is suitable to prepare the transfer vector, by insertion of the CHIKV polynucleotide(s) necessary for the expression of CHIKV structural protein(s), in particular CHIKV VLPs.
- 30 The invention thus relates to a transfer vector, which is used for the preparation of recombinant MV-CHIKV particles when rescued from helper cells. The transfer vector of the invention is advantageously a plasmid, in particular a plasmid obtained from a Bluescript plasmid.

The invention also concerns the use of the transfer vector to transform cells suitable for rescue of viral MV-CHIKV particles, in particular to transfect or to transduce such cells respectively with plasmids or with viral vectors harbouring the nucleic acid construct of the invention, said cells being selected for their capacity to express required measles virus proteins for appropriate replication, transcription and encapsidation of the recombinant genome of the virus corresponding to the nucleic acid construct of the invention in recombinant, infectious, replicative MV-CHIKV particles.

10 The invention also relates to the cells or cell lines thus transformed by the transfer vector of the invention and by further polynucleotides providing helper functions and proteins.

Polynucleotides are thus present in said cells, which encode proteins that include in particular the N, P and L proteins of a measles virus (i.e., native MV proteins or functional variants thereof capable of forming ribonucleoprotein (RNP) complexes), preferably as stably expressed proteins at least for the N and P proteins functional in the transcription and replication of the recombinant viral MV-CHIKV particles. The N and P proteins may be expressed in the cells from a plasmid comprising their coding sequences or may be expressed from a DNA molecule inserted in the genome of the cell. The L protein may be expressed from a different plasmid. It may be expressed transitory. The helper cell is also capable of expressing a RNA polymerase suitable to enable the synthesis of the recombinant RNA derived from the nucleic acid construct of the invention, possibly as a stably expressed RNA polymerase. The RNA polymerase may be the T7 phage polymerase or its nuclear form (nlst7).

In an embodiment, the cDNA clone of a measles virus is from the same measles virus strain as the N protein and/or the P protein and/or the L protein. In another embodiment, the cDNA clone of a measles virus is from a different strain of virus than the N protein and/or the P protein and/or the L protein.

The invention thus relates to a process for the preparation of recombinant infectious measles virus particles comprising :

1) transferring, in particular transfecting, the nucleic acid construct of the invention or the transfer vector containing such nucleic acid construct in a helper cell line which also expresses proteins necessary for transcription, replication and encapsidation of the antigenomic (+)RNA sequence of MV from its cDNA and under conditions enabling viral particles assembly and

2) recovering the recombinant infectious MV-CHIKV virus expressing at least one structural protein of CHIKV.

According to a particular embodiment this process comprises:

1) transfecting helper cells with a nucleic acid construct according to the invention with a transfer vector, wherein said helper cells are capable of expressing helper functions to express an RNA polymerase, and to express the N, P and L proteins of a MV virus ;

2) co-cultivating said transfected helper cells of step 1) with passaged cells suitable for the passage of the MV attenuated strain from which the cDNA originates ;

3) recovering the recombinant infectious MV-CHIKV virus expressing at least one structural protein of CHIKV.

According to another particular embodiment of the invention the method for the production of recombinant infectious MV-CHIKV virus comprises :

1) recombining a cell or a culture of cells stably producing a RNA polymerase, the nucleoprotein (N) of a measles virus and the polymerase cofactor phosphoprotein (P) of a measles virus, with a nucleic acid construct of the invention and with a vector comprising a nucleic acid encoding a RNA polymerase large protein (L) of a measles virus, and

2) recovering the infectious, MV-CHIKV virus from said recombinant cell or culture of recombinant cells.

According to a particular embodiment of said process, recombinant MV are produced, which express CHIKV structural protein, in particular CHIKV VLPs wherein the particles express a combination of antigens, e.g. CE3E26KE1 antigens of CHIK virus. As an illustration, a process to rescue recombinant MV expressing CHIKV structural proteins, in particular CHIKV VLPs comprises the steps of :

- 1) cotransfecting helper cells, in particular HEK293 helper cells, that stably express T7 RNA polymerase, and measles N and P proteins with (i) a transfer vector, in particular a plasmid, comprising cDNA encoding the full-length antigenomic (+)RNA of a measles virus recombined with at least one polynucleotide encoding CHIKV structural proteins, for example encoding the CHIKV-CE3E26KE1 antigens and with (ii) a vector, especially a plasmid, encoding the MV L polymerase cDNA;
 - 2) cultivating said cotransfected helper cells in conditions enabling the production of MV-CHIKV recombinant virus;
 - 3) propagating the thus produced recombinant virus by co-cultivating said helper cells of step 2) with cells enabling said propagation such as Vero cells;
 - 4) recovering replicating MV-CHIKV recombinant virus and CHIKV structural proteins, in particular CHIKV Virus Like Particles, in particular CHIKV-CE3E26KE1 VLPs.
- Such a process, together with the constructs and conditions used are illustrated in Figure 1B.

As used herein, "*recombining*" means introducing at least one polynucleotide into a cell, for example under the form of a vector, said polynucleotide integrating (entirely or partially) or not integrating into the cell genome (such as defined above).

According to a particular embodiment, recombination can be obtained with a first polynucleotide, which is the nucleic acid construct of the invention. Recombination can, also or alternatively, encompass introducing a polynucleotide, which is a vector encoding a RNA polymerase large protein (L) of a measles virus, whose definition, nature and stability of expression has been described herein.

In accordance with the invention, the cell or cell lines or a culture of cells stably producing a RNA polymerase, a nucleoprotein (N) of a measles virus and a polymerase cofactor phosphoprotein (P) of a measles virus is a cell or cell line as defined in the present specification or a culture of cells as defined in the present specification, *i.e.*, are also recombinant cells to the extent that they have been modified by the introduction of one or more polynucleotides as defined above. In a particular embodiment of the invention, the cell or cell line or culture of cells, stably

producing the RNA polymerase, the N and P proteins, does not produce the L protein of a measles virus or does not stably produce the L protein of a measles virus, e.g., enabling its transitory expression or production.

- 5 The production of MV-CHIKV virus of the invention may involve a transfer of cells transformed as described herein. "*Transfer*" as used herein refers to the plating of the recombinant cells onto a different type of cells, and particularly onto monolayers of a different type of cells. These latter cells are competent to sustain both the replication and the production of infectious MV-CHIKV virus *i.e.*, respectively the formation of
- 10 infectious viruses inside the cell and possibly the release of these infectious viruses outside of the cells. This transfer results in the co-culture of the recombinant cells of the invention with competent cells as defined in the previous sentence. The above transfer may be an additional, *i.e.*, optional, step when the recombinant cells are not efficient virus-producing culture *i.e.*, when infectious MV-CHIKV virus cannot be
- 15 efficiently recovered from these recombinant cells. This step is introduced after further recombination of the recombinant cells of the invention with nucleic acid construct of the invention, and optionally a vector comprising a nucleic acid encoding a RNA polymerase large protein (L) of a measles virus.
- 20 In a particular embodiment of the invention, a transfer step is required since the recombinant cells, usually chosen for their capacity to be easily recombined are not efficient enough in the sustaining and production of recombinant infectious MV-CHIKV virus. In said embodiment, the cell or cell line or culture of cells of step 1) of the above-defined methods is a recombinant cell or cell line or culture of recombinant
- 25 cells according to the invention.

- Cells suitable for the preparation of the recombinant cells of the invention are prokaryotic or eukaryotic cells, particularly animal or plant cells, and more particularly mammalian cells such as human cells or non-human mammalian cells or avian cells
- 30 or yeast cells. In a particular embodiment, cells, before recombination of its genome, are isolated from either a primary culture or a cell line. Cells of the invention may be dividing or non-dividing cells.

According to a preferred embodiment, helper cells are derived from human embryonic kidney cell line 293, which cell line 293 is deposited with the ATCC under No. CRL-1573. Particular cell line 293 is the cell line disclosed in WO2008/078198 and referred to in the following examples.

5

According to another aspect of this process, the cells suitable for passage are CEF cells. CEF cells can be prepared from fertilized chicken eggs as obtained from EARL Morizeau, 8 rue Moulin, 28190 Dangers, France, or from any other producer of fertilized chicken eggs.

10

The process which is disclosed according to the present invention is used advantageously for the production of infectious replicative MV-CHIKV virus appropriate for use as immunization compositions.

15

The invention thus relates to an immunogenic composition whose active principle comprises infection replicative MV-CHIKV virus rescued from the nucleic acid construct of the invention and in particular obtained by the process disclosed.

20

As defined herein the nucleic acid construct of the invention and the MV-CHIKV virus of the invention encode or express at least one CHIKV structural protein.

25

By "Chikungunya virus structural protein" is meant a "protein" as defined herein the sequence of which is identical to a counterpart in a strain of CHIKV, including a polypeptide which is a native mature or precursor of a structural protein of CHIKV or is a fragment thereof or a mutant thereof as defined herein in particular a fragment or a mutant having at least 50%, at least 80%, in particular advantageously at least 90% or preferably at least 95% amino acid sequence identity to a naturally occurring Chikungunya virus capsid or envelope protein. Amino acid sequence identity can be determined by alignment by one of skill in the art using manual alignments or using the numerous alignment programs available (for example, BLASTP – <http://blast.ncbi.nlm.nih.gov/>). Fragments or mutants of CHIKV structural proteins of the invention may be defined with respect to the particular amino acid sequences illustrated herein.

30

According to the invention, the polynucleotide encoding at least one of the structural proteins of CHIKV encodes one or a plurality of proteins selected in the group of structural glycoproteins, structural polypeptides and capsid protein.

5 In a particular embodiment, the glycoproteins encompass the envelope glycoproteins E1, E2 and E3 envelope glycoproteins. The polypeptides encompass the 6K polypeptide and the capsid protein. In the following paragraphs the terms protein or glycoprotein will be used interchangeably to designate the E1, E2, or E3 glycoproteins or their combinations.

10 According to a particular embodiment of the invention, the polynucleotide encoding the CHIKV structural proteins is selected in the group of:

- A polynucleotide encoding one of the E1, E2, E3, 6K or C proteins;
- A fusion polynucleotide encoding several proteins selected among the E1, E2, 15 E3, 6K and C proteins;
- A polynucleotide encoding the E3-E2-6K-E1 polyprotein.
- A polynucleotide which encodes the C-E3-E2-6K-E1 polyprotein and in particular the open reading frame (ORF) derived from a CHIKV genome or a corresponding cDNA which encodes said polyprotein;
- 20 - Any of these polynucleotides which has been modified in order to encode a mutated form of one or more of these proteins, in particular a mutated form of the E2 protein.

A particular polynucleotide in this respect encodes a soluble form of the E2 protein (sE2) or encodes the ectodomain of the E2 protein or its soluble form (sE2 Δ stem). In 25 a particular embodiment, the polynucleotide encodes one of the following polypeptides: E3-sE2-6K-E1, E3-sE2 Δ stem-6K-E1, C-E3-sE2-6K-E1, and C-E3-sE2 Δ stem-6K-E1.

As used herein, the term "ectodomain" means the domain of glycoprotein E2 which extends outside the viral particle and is responsible for attachment to and entry into 30 cells during infection by CHIKV viral particles.

According to a particular embodiment, the polynucleotide encodes a single epitope of a CHIKV structural protein or encodes a polyepitope resulting from expression of

repeated epitopes (having identical or similar sequences) or multiple distinct epitopes of one or many CHIKV structural proteins.

By way of illustration a polyepitope is formed by fusion of repeated polynucleotides encoding the E2 EP3 single epitope located at N-terminus of the E2 glycoprotein proximal to a furin E2/E3-cleavage site. The amino acid sequence of the E2 EP3 epitope is disclosed in Kam Y. W et al. (EMBO Mol Med 4, 330-343) and as SEQ ID NO: 33.

- 10 According to a particular embodiment of the invention, several polynucleotides wherein each polynucleotide encodes at least one structural protein of CHIKV are combined or fused to form a polynucleotide encoding several structural proteins of the CHIKV. These polynucleotides may distinguish from each other by the fact that they code for proteins of various strains of the CHIKV. As a result, the polynucleotide
15 encodes a polyepitope as described herein, such as a polyepitope of single E2 EP3 epitope.

The polynucleotide(s) encoding at least one structural protein(s) of CHIKV is (are) cloned in the cDNA molecule encoding the full-length infectious antigenomic (+)RNA strand of a measles virus, to give rise to the nucleic acid construct of the invention,
20 possibly into different sites.

According to one aspect of the invention, a polynucleotide encoding at least one Chikungunya virus (CHIKV) structural protein is derived from the genome of isolated and purified wild strain(s) of CHIKV. Wild strains of CHIKV can be for example the
25 Ross strain (GenBank: AF490259.3), or the S27 strain (GenBank: AF339485.1), both isolated from patients during the 1952 Tanzania outbreak or, a strain isolated during the Senegal 1983 outbreak and named Ae. fuscifer (GenBank: AY726732.1).

30 According to another aspect of the present invention, a polynucleotide encoding at least one CHIKV structural protein derives from the following purified and isolated wild strains of CHIKV: 05.61, 05.115, 05.209, 06.21, 06.27 and 06.49, which have been described in WO2007/105111. The nearly complete genome sequences of these CHIKV isolates representing distinct geographic origins, time points and clinical

forms of the Indian Ocean outbreak of Chikungunya virus have been sequenced and disclosed in WO2007/105111. 11,601 nucleotides were determined, corresponding to positions 52 (5'NTR) to 11,667 (3'NTR, end of third Repeat Sequence Element) in the nucleotide sequence of the 1952 Tanzanian isolate S27 taken as a reference (total length 11,826 nt).

The genome sequences of the isolates 05.61, 05.115, 05.209, 06.21, 06.27 and 06.49 presented in WO2007/105111 and from which the polynucleotides according to the present invention may be derived in a particular embodiment of the invention are organized as follows. Coding sequences consist of two large open reading frames (ORF) of 7,422 nt and 3,744 nt encoding the nonstructural polyprotein (2,474 amino-acids) and the structural polyprotein (1,248 amino-acids), respectively. The non structural polyprotein is the precursor of proteins nsP1 (535 aa), nsP2 (798 aa), nsP3 (530 aa) and nsP4 (611 aa), and the structural polyprotein is the precursor of proteins C (261 aa), p62 (487 aa, precursor to E3 - 64 aa - and E2 - 423 aa), 6K (61 aa), and E1 (439 aa). Cleavage sites characteristic of the alphavirus family in the non-structural and structural polyproteins are conserved. Glycosylation sites in E3, E2 and E1 are also conserved. The disclosure of the genome sequences is incorporated herewith by reference.

According to one embodiment, a polynucleotide encoding the CHIKV structural protein(s) is derived from the genome of the following group of wild strains of CHIKV designated: 06.115, 06.21, 06.27 and 06.49, previously described.

The term "derive" appearing in the definition of the polynucleotides merely specifies that the sequence of said polynucleotide may be identical to the corresponding sequence in a CHIKV strain or may vary to the extent that it encodes structural protein(s) of CHIKV that meet(s) the definition of the "protein" according to the present invention. Accordingly, the term does not restrict the production mode of the polynucleotide.

The polynucleotide(s) and nucleic acid construct of the invention may rather be prepared in accordance with any known method in the art and in particular may be

cloned, obtained by polymerization especially using PCR methods or may be synthesized.

The nucleic acid constructs of the invention are further defined as including one of the following polynucleotides encoding at least one CHIKV structural proteins.

According to a particular embodiment, a polynucleotide which encodes one or several structural protein(s) of CHIKV encodes a soluble form of the glycoprotein E2. As an example such a polynucleotide comprises a coding domain which has the sequence of SEQ ID NO: 2, 4, 6, 8.

In a particular embodiment, a polynucleotide which encodes one or several structural protein(s) of CHIKV encodes the E2 ectodomain. As an example, such a polynucleotide comprises a coding domain which has the sequence of SEQ ID NO: 10, 12, 14.

In another embodiment of the invention, the polynucleotide encoding a soluble form of the glycoprotein E2 encodes one polypeptide having an amino acid sequence selected in the group of SEQ ID NO: 3, 5, 7, 9.

In another embodiment of the invention, the polynucleotide encoding the ectodomain of the glycoprotein E2 encodes one polypeptide having an amino-acid sequence selected in the group of SEQ ID NO: 11, 13, 15.

According to a particular embodiment of the invention, the polynucleotide encoding structural protein of CHIKV encompasses one of the above defined nucleotide sequences encoding the soluble form of the E2 glycoprotein or the ectodomain of said protein and comprises further, a polynucleotide encoding one of the E3, E1, 6K or C protein, or a polynucleotide encoding any combination thereof.

Accordingly particular polynucleotides of the invention encoding structural polyprotein E2-6K-E1 of France/2010 strains isolated in Fréjus are selected in the following group: polynucleotides comprising a coding domain which has the sequence of SEQ ID NO: 16 (GenBank: CCA61130.1) and 20 (GenBank: CCA61131.1).

Preferred polynucleotide of the invention encodes structural proteins C-E3-E2-6K-E1 from a strain of CHIKV. In a particular embodiment, the polynucleotide encodes polyprotein C-E3-E2-6K-E1 of one of the strains named S27 or 06.49 and have
5 respectively the sequences of SEQ ID NO: 20 and 27.

In another embodiment of the invention, the polynucleotide which is used encodes the E2 EP3 epitope or a polyepitope formed with a repetition of this epitope or comprising such repetition. This polynucleotide has in particular the nucleotide
10 sequence disclosed as SEQ ID No: 32.

According to a preferred embodiment, the invention also concerns modifications and optimization of the polynucleotide to allow an efficient expression of the Chikungunya virus proteins at the surface of chimeric infectious particles of MV-CHIKV in the host.

According to this embodiment, optimization of the polynucleotide sequence can be operated avoiding cis-active domains of nucleic acid molecules: internal TATA-boxes, chi-sites and ribosomal entry sites; AT-rich or GC-rich sequence stretches; ARE, INS, CRS sequence elements; repeat sequences and RNA secondary
20 structures ; cryptic splice donor and acceptor sites, branch points.

The optimized polynucleotides may also be codon optimized for expression in a specific cell type, in particular may be modified for the Maccaca codon usage or for the human codon usage. This optimization allows increasing the efficiency of
25 chimeric infectious particles production in cells without impacting the expressed protein(s).

In particular, the optimization of the polynucleotide encoding the CHIKV protein(s) may be performed by modification of the wobble position in codons without impacting
30 the identity of the amino acid residue translated from said codon with respect to the original one.

Optimization is also performed to avoid editing-like sequences from Measles virus. The editing of transcript of Measles virus is a process which occurs in particular in

the transcript encoded by the *P* gene of Measles virus. This editing, by the insertion of extra G residues at a specific site within the *P* transcript, gives rise to a new protein truncated compared to the *P* protein. Addition of only a single G residue results in the expression of the *V* protein, which contains a unique carboxyl terminus
 5 (Cattaneo R *et al.*, Cell. 1989 Mar 10;56(5):759-64).

In the polynucleotides according to this particular embodiment of the invention, the following editing-like sequences from Measles virus can be mutated: AAAGGG, AAAAGG, GGGAAA, GGGGAA, as well as their complementary sequence:
 10 TTCCCC, TTTCCC, CCTTTT, CCCCTT. For example, AAAGGG can be mutated in AAAGGC, AAAAGG can be mutated in AGAAGG or in TAAAGG or in GAAAGG, and GGGAAA in GCGAAA.

An embodiment of a modified and optimized polynucleotide according to the present
 15 invention is as defined in SEQ ID NO:29. This polynucleotide encodes the soluble form of the envelope protein E2 without the stem region.

An embodiment of a modified and optimized polynucleotide encoding all the structural proteins C-E3-E2- 6K-E1 is as defined in SEQ ID NO: 31.
 20

These optimized polynucleotides according to this particular embodiment of the invention as defined in SEQ ID NO: 29 and 31, present mutations in BsiWI and BssHII sites inside the sequences but not at the end of these sequences in order to maintain the sites for cloning purposes.

25 Therefore, according to this particular embodiment the invention provides nucleic acid constructs comprising polynucleotides which increase the efficiency of chimeric MV-CHIKV infectious particles production.

30 Other optimized polynucleotides comprising the sequences coding for structural proteins of the CHIKV and also suitable for use in the nucleic acid constructs of the invention are optimized fusion polynucleotides encoding one of the following combinations of structural proteins: E3-E2-6K-E1, E3-sE2-6K-E1, E3-sE2 Δ stem-6K-E1, C-E3-E2-6K-E1, C-E3-sE2-6K-E1, and C-E3-sE2 Δ stem-6K-E1.

The invention also relates to nucleic acid construct wherein the polynucleotide encoding at least one structural protein of CHIKV encodes one of the following polypeptides.

5

Examples of amino acid sequences of CHIK virus structural proteins according to preferred embodiments of the invention and related to a soluble form of the glycoprotein E2 from the following strains designated 05.115, 06.21, 06.27 and 06.49, are as defined in SEQ ID NO: 3, 5, 7, 9.

10

Examples of amino acid sequences of CHIK virus structural proteins according to preferred embodiments of the invention and related to the ectodomain of the glycoprotein E2 from the following strains designated 05.115, 06.21, 06.27 and 06.49, are as defined in SEQ ID NO: 11, 13, 15.

15

In a particular embodiment, the invention relates to fusion proteins constituted by the structural proteins E2-6K-E1 of a France/2010 strain isolated in Fréjus. These proteins result respectively from the expression of the polynucleotides which have the sequence of SEQ ID NO: 16 (GenBank: CCA61130.1) and 18 (GenBank: CCA61131.1). Their sequences are defined respectively in SEQ ID NO: 17 and 19.

20

In a particularly preferred embodiment, the invention concerns fusion proteins constituted by all CHIKV structural proteins. These proteins results from the expression of the polynucleotides encoding all the structural proteins C-E3-E2- 6K-E1 and are defined in SEQ ID NO: 21, 22, 23, 24, 25, 26 and 28.

25

The structural proteins C-E3-E2-6K-E1 obtained are able to auto-assemble into CHIKV virus-like-particles (VLPs), in the CHIKV-MV particles.

30

As used herein, the term "virus-like particle" (VLP) refers to a structure that in at least one attribute resembles a virus but which has not been demonstrated to be infectious as such. Virus Like Particles in accordance with the invention do not carry genetic information encoding the proteins of the Virus Like Particles, in general, virus-like particles lack a viral genome and, therefore, are noninfectious and non replicative. In

accordance with the present invention, Virus Like Particles can be produced in large quantities and are expressed together with CHIKV-MV recombinant particles.

5 In a particular embodiment, the invention relates to a soluble form of the glycoprotein E2 without the stem region from the strain of CHIKV designated 06.49. This glycoprotein results from the expression of the modified and optimized polynucleotide as defined in SEQ ID NO:29. Its sequence is defined in SEQ ID NO: 30.

10 According to another aspect, the invention relates to recombinant CHIKV-Measles virus particles expressing the Chikungunya virus structural protein(s) as defined herein, in particular by reference to their nucleic acid and polypeptide sequences. The recombinant CHIKV-MV virus advantageously expresses the CHIKV structural proteins as VLPs.

15 The invention also concerns the association, in a composition, of virus-like particles of CHIKV structural proteins, in particular VLPs of C-E3-E2-6K-E1, with CHIKV-MV infectious replicative virus particles.

20 According to a preferred embodiment of the invention, the recombinant measles virus vector is designed in such a way and the production process involves cells such that the virus particles produced in helper cells transfected or transformed with said vector, originated from a measles virus strain adapted for vaccination, enable the production of recombinant Measles-Chikungunya infectious and replicative virus and the production of CHIKV-VLPs for use in immunogenic compositions, preferably
25 protective or even vaccine compositions.

Advantageously, the genome of the recombinant Measles-Chikungunya infectious virus of the invention is replication competent. By "replication competent", it is meant a nucleic acid, which when transduced into a helper cell line expressing the N, P and
30 L proteins of a MV, is able to be transcribed and expressed in order to produce new viral particles.

Replication of the recombinant virus of the invention obtained using MV cDNA for the preparation of the recombinant genome of MV-CHIKV can also be achieved *in vivo* in

the host, in particular the human host to which recombinant MV-CHIKV is administered.

5 The invention also concerns a composition or an assembly of active ingredients which comprises the recombinant Measles-Chikungunya replicative virus in association with VLPs of CHIKV structural proteins, such as VLPs of CE3E26KE1 proteins. These compositions or assemblies induce an immune response, in particular a protective immune response, against Chikungunya virus, and in particular elicit antibodies production directed against Chikungunya virus structural proteins
10 and/or elicit a cellular immune response against CHIKV infection. These compositions accordingly may comprise a suitable vehicle for administration e.g. a pharmaceutically acceptable vehicle to a host, especially a human host and may further comprise but not necessarily adjuvant to enhance immune response in a host. The inventors have indeed shown that the administration of the active ingredients of
15 the invention may elicit an immune response without the need for adjuvantation.

The invention relates in particular to a composition for administration to children.

20 The invention is also directed to an immunogenic composition, in particular a vaccine composition and in particular to a vaccine composition for administration to children. Said composition or vaccine is used for protection against CHIKV infection in a prophylactic treatment. Such a vaccine composition has advantageously active principles (active ingredients) which comprise recombinant Measles- Chikungunya infectious replicative viral particles rescued from the vector which has been defined
25 herein associated with VLPs of CHIKV structural proteins, such as VLPs of CE3E26KE1 proteins.

In the context of the invention, the terms "associated" or "in association" refer to the presence, in a unique composition, of both MV-CHIKV recombinant viral particles
30 and CHIKV structural proteins, in particular as VLPs, usually as physically separate entities.

The invention also concerns the recombinant MV-CHIKV infectious replicating virus particles in association with CHIKV-Virus structural proteins, in particular CHIKV-

Virus Like Particles expressing CHIKV structural proteins, in particular CHIKV-CE3E26KE1 VLPs or the composition according to the invention, for use in the treatment or the prevention of an infection by Chikungunya virus in a subject, in particular in a human.

5

The invention also concerns MV-CHIKV infectious, replicative virus and associated CHIKV-Virus structural proteins, in particular associated VLPs of CHIKV structural proteins, such as VLPs of CE3E26KE1 proteins for use in an administration scheme and according to a dosage regime that elicit an immune response, advantageously a protective immune response, against CHIKV virus infection or induced disease, in particular in a human host.

10

The administration scheme and dosage regime may require a unique administration of a selected dose of MV-CHIKV infectious, replicative virus and associated CHIKV structural proteins, in particular associated VLPs of CHIKV structural proteins, such as VLPs of CE3E26KE1 proteins.

15

Alternatively it may require multiple doses administration in a prime-boost regimen. Priming and boosting may be achieved with identical active ingredients consisting of MV-CHIKV infectious, replicative virus and associated CHIKV structural proteins, in particular associated VLPs of CHIKV structural proteins, such as VLPs of CE3E26KE1 proteins.

20

Alternatively priming and boosting administration may be achieved with different active ingredients, involving MV-CHIKV infectious, replicative virus and associated CHIKV structural proteins, in particular associated VLPs of CHIKV structural proteins, such as VLPs of CE3E26KE1 proteins in at least one of the administration steps and other active immunogens of CHIKV, such as CHIKV proteins or VLPs expressing C-E3-E2-6K-E1 polyprotein, in other administration steps.

25

30

The invention also concerns an assembly of different active ingredients including as one of these ingredients MV-CHIKV infectious, replicative virus and associated CHIKV structural proteins, in particular associated VLPs of CHIKV structural proteins,

such as VLPs of CE3E26KE1 proteins. The assembly of active ingredients is advantageously for use in immunization of a host, in particular a human host.

The inventors have shown that administration of MV-CHIKV infectious, replicative virus and associated VLPs of CHIKV structural proteins elicit an immune response and especially elicit antibodies that are cross-reactive for various CHIKV strains, at least in the ECSA genotype. Accordingly, it has been shown that administration of the active ingredients according to the invention, when prepared with the coding sequences of a particular strain of CHIKV, can elicit an immune response against a group of strains of CHIKV, in particular a group of strains of the ECSA genotype, in particular a group of strains encompassing CHIKV strain India, CHIKV strain Congo, CHIKV strain Thailand and CHIKV strain La Réunion.

Considering available knowledge on doses of vaccines suitable for other pathogens (such as HBV or HPV) which involve the administration of Virus Like Particles (VLP) and also for known human MV vaccines, the inventors have determined that the recovery of CHIKV-VLPs with the recombinant MV-CHIKV virus enables proposing administration of effective low doses of the active ingredients. Indeed, considering that the recombinant MV-CHIKV virus enables production of around 10^4 CHIKV-VLPs per recombinant MV-CHIKV replicated particle, and considering that the currently known doses for human MV vaccines are in the range of 10^3 to 10^4 pfu, a suitable dose of recombinant MV-CHIKV virus to be administered may be in the range of 0.1 to 10ng, in particular 0.2 to 6ng, and possibly as low as 0.2 to 2ng. For comparison doses of VLPs administered in the case of HBV or HPV vaccines are in the range of 10 μ g which means that a dose of recombinant MV-CHIKV vaccine could comprise around 2 000 or up to 5 000 to 10 000 times less VLPs.

According to a particular embodiment of the invention, the immunogenic composition or the vaccine defined herein may also be used for protection against an infection by the measles virus.

RECOMBINANT MEASLES VIRUS EXPRESSING CHIKUNGUNYA VIRUS POLYPEPTIDES AND THEIR APPLICATIONS

FIELD OF THE INVENTION

5

The invention is directed to recombinant Measles virus expressing Chikungunya virus polypeptides, and concerns in particular virus like particles (VLP) that contain envelope and capsid proteins of a Chikungunya virus at their surface. These particles are recombinant infectious particles able to replicate in a host after an administration.

10

The invention provides means, in particular nucleic acids, vectors, cells and rescue systems to produce these recombinant infectious particles. The invention also relates to the use of these recombinant infectious particles, in particular under the form of a composition, more particularly in a vaccine formulation, for the treatment or prevention of an infection by Chikungunya virus.

15

BACKGROUND OF THE INVENTION

Chikungunya virus (CHIKV) is a positive-strand RNA virus of the genus *Alphavirus* within the family of *Togaviridae*, first isolated in Tanzania in 1952.

20

Infection by this virus causes human disease that is characterized by symptoms similar to dengue fever, with an acute febrile phase during two to five days, followed by a prolonged arthralgic disease that affects the joints of the extremities. CHIKV is endemic in Africa, India and South-East Asia and is transmitted by *Aedes* mosquitoes through an urban or sylvatic transmission cycle. In 2006, an outbreak of CHIKV fever occurred in numerous islands of the Indian Ocean (the Comoros, Mauritius, Seychelles, Madagascar, Reunion island...), before jumping to India where an estimated 1.4 million cases have been reported. More recently, imported infections have been described in Europe, and around 200 endemic cases have been reported in Italy (Jose, J. *et al.*, A structural and functional perspective of alphavirus replication and assembly. *Future Microbiol*, 2009. 4(7): p. 837-56). Clinically, this CHIKV epidemic was accompanied by more severe symptoms than previous outbreaks, with reports of severe polyarthralgia and myalgia, complications and deaths.

30

DESCRIPTION OF THE DRAWINGS

Figure 1 Schematic representation of ORFs for structural proteins of Chikungunya virus and for the backbone of MV genome - MV-CHIKV constructs including antigens of said CHIK virus for expression by Measles virus are proposed.

Figure 1B. Rescue of recombinant MV expressing CHIKV VLP

Figure 2 Immunofluorescence detection of E2 antigen in Vero cells infected by recombinant MV-CHIKV for 24h at MOI 0.1
E2 was detected using the anti-E2 Mab 3E4 used at 1/100 dilution and secondary antibody were used at 1/5000 dilution.

Figure 3: Expression of E2 and capsid proteins by MV-CHIKV vectors.

Cell lysates (cells) and supernatants (SN) of Vero cells infected for 24 h by MV-sE2 Δ stem, and MV-CE3E26KE1 analyzed by western blot. E2 was probed with the 3E4 Mab, and C protein was detected using an anti-capsid Mab (from P. Desprès) used at 1/100 dilution and secondary antibodies were used at 1/5000 dilution.

Figure 4. Electron microscopy analysis of CHIKV VLPs secreted in the supernatant of Vero cells infected by MV- CE3E26KE1 recombinant virus at MOI 0.1. Scale bar 200 nm (left) and 100 nm (right). Red arrows indicate the specific arrangement of spikes on particles surface and the icosahedral symmetry of the capsid protein inside the particles.

Figure 5. Sequence of the truncated sE2 expressed by MV-sE2 recombinant virus (156 aa, 19 kDa).

Figure 6: Growth kinetics of recombinant MV-sE2 Δ stem, and MV-CE3E26KE1 viruses compared with standard MV on Vero cells (MOI 0.01). Cell-associated virus titers are indicated in TCID₅₀.

Figure 7: Immunization and challenge schedule of example 2.

Figure 8: Survival curve of mice lethally challenged with 100 PFU of CHIKV-06-49 after two immunizations with MV-CE3E26KE1 recombinant virus.

Figure 9: Immunization and challenge schedule of example 3.

5

Figure 10: Survival curve of mice lethally challenged with 100 PFU of CHIKV-06-49 after a single immunization with MV-CE3E26KE1 recombinant virus.

Figure 11: Immunization and challenge schedule of example 4.

10

Figure 12: Survival curve of mice lethally challenged with 100 PFU of CHIKV-06-49 after immunization with different doses of MV-CE3E26KE1 recombinant virus.

Figure 13: Passive transfer of immune sera and challenge schedule of example 5.

15

Figure 14: Survival curve of mice lethally challenged with 100 PFU of CHIKV-06-49 after passive transfer of MV-CE3E26KE1 immune sera.

Figure 15: Cell-mediated immune responses elicited in splenocytes of CD46-IFNAR mice immunized by a single injection of 10⁶ TCID₅₀ of MV-CHIKV.

20

Figure 16: Immunization and challenge schedule of example 6.

Figure 17: Survival curve of MV pre-immune mice lethally challenged with 100 PFU of CHIKV-06-49 after immunization with MV-CE3E26KE1.

25

Figure 18: PRNT assays performed against CHIK prior to first immunization on day 90 (prior to boost) and day 111 (21 days after boost).

30

EXAMPLES

Construction and characterization of recombinant Measles virus vectors expressing Chikungunya virus proteins.

The inventors designed three Chikungunya Virus antigens based on peptide sequences from native proteins of the strain 06-49 of Chikungunya virus. The native proteins enabling preparation of these peptide sequences were the five structural proteins which consist of capsid (C) envelope and accessory proteins E1, E2, E3 and 6K.

The first construct was directed to the expression of the soluble form of the envelope protein E2 (sE2), the second construct to the expression of the sE2 without the stem region (sE2 Δ stem), and the third construct was directed to the expression of all viral structural proteins (C-E3-E2-6K-E1) (Fig. 1). The experiment protocols have been described herein with respect to this latter construct.

Cell culture. Vero (African green monkey kidney) cells were maintained in DMEM GlutaMAX™ (Gibco-BRL) supplemented with 5% heat-inactivated fetal calf serum (FCS, Invitrogen, Frederick, MD). HEK-293-T7-MV helper cells (WO2008/078198) used for recombinant measles virus rescue were grown in DMEM supplemented with 10% FCS.

Construction of pTM-MV Schw-CE3E26KE1. The plasmid pTM-MV Schw, which contains an infectious MV cDNA corresponding to the anti-genome of the Schwarz MV vaccine strain, has been described elsewhere (Combretet, C., *et al.*, A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. *J Virol*, 2003. 77(21): p. 11546-54). The cDNA encoding for the structural CE3E26KE1 CHIKV antigens was generated by chemical synthesis (GenScript, USA). It contains the sequence for viral structural proteins C-E3-E2-6K-E1 from CHIKV strain 06-49 (WO2007/105111). The complete sequence respects the "rule of six", which stipulates that the number of nucleotides into the MV genome must be a multiple of 6, and contains *BsiWI* restriction site at the 5' end, and *BssHII* at the 3' end. The sequence was optimized for measles virus expression in mammalian cells. This cDNA was inserted into *BsiWI*/*BssHII*-digested pTM-MV Schw-ATU2, which contains an additional transcription unit (ATU) between the phosphoprotein (P) and the matrix (M) genes of the Schwarz MV genome (Combretet, C., *et al.*, A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. *J Virol*, 2003.

77(21): p. 11546-54). The resulting plasmid was designated as pTM-MVSchw-CE3E26KE1.

Rescue of recombinant MV-CE3E26KE1. Rescue of recombinant Schwarz MV-CHIKV from the plasmid pTM-MVSchw-CE3E26KE1 was performed as previously described using a rescue system previously described (Radecke, F., *et al.*, Rescue of measles viruses from cloned DNA. *Embo J*, 1995. 14(23): p. 5773-84 ; WO2008/078198). Viral titers were determined by endpoint limit dilution assay on Vero cells and TCID₅₀ was calculated by using the Kärber method.

Immunofluorescence. Immunofluorescence staining was performed on infected cells, as described elsewhere (Lucas, M., *et al.*, Infection of mouse neurons by West Nile virus is modulated by the interferon-inducible 2'-5' oligoadenylate synthetase 1b protein. *Immun. Cell Biol.*, 2003. 81: p. 230-236). Cells were probed with mouse anti-E2 (3E4) and anti-capsid antibodies. Cy3-conjugated goat anti mouse IgG antibody Cy3 conjugated (Jackson Immunoresearch laboratories), was used as secondary antibody.

Western blot assays. Protein lysates from Vero cells infected with recombinant virus were fractionated by SDS-PAGE gel electrophoresis and transferred to cellulose membranes (Amersham Pharmacia Biotech). The blots were probed with mouse Mab 3E4 anti-E2 and anti-capsid. A goat anti-mouse immunoglobulin G (IgG)-horseradish peroxidase (HRP) conjugate (Amersham) was used as a secondary antibody. Peroxidase activity was visualized with an enhanced chemiluminescence detection kit (Pierce).

Analysis of VLP production by electron microscopy. Vero cells (3 x T-150 flasks) were infected with MV-CHIKV recombinant virus at MOI 1. Supernatants collected after 36 h of infection were clarified by centrifugation at 3000 rpm for 30 min, layered on 20% sucrose cushion in PBS and centrifuged at 41,000 rpm for 2 h in a SW41 rotor. Pellets were resuspended in PBS with 1% BSA and analysed by electron microscopy. Negative staining was made by 2% uranyl acetate on copper grids coated with carbon and glow discharged just before use. The samples were observed at 80kV with a Jeol JEM1200 (Tokyo, Japan) transmission electron

microscope. Images were recorded using an Eloise Keenvue camera and the Analysis Pro-software version 3,1 (Eloise SARL, Roissy, France).

Mice experiments. CD46-IFNAR mice susceptible to MV infection were produced as previously described (Combredet, C., *et al.*, A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice. *J Virol*, 2003. 77(21): p. 11546-54). Mice were housed under specific pathogen-free conditions at the Pasteur Institute animal facility. For immunization, six-week-old CD46-IFNAR mice were inoculated intraperitoneally (i.p.) with 10^5 TCID₅₀ of recombinant MV-CE3E26KE1 or MV. For protection assays, immunized mice were i.p inoculated with 100 pfu of CHIKV 06-49 strain and mortality was followed for 2 weeks. All experiments were approved and conducted in accordance with the guidelines of the Office of Laboratory Animal Care at Pasteur Institute. For passive transfer study, CD46-IFNAR mice were inoculated intraperitoneally with 20µl of pooled sera from 6 mice immunized with 10^5 TCID₅₀ of MV-CE3E26KE1. Control mice received either 20 µl of pooled sera from mice immunized with 10^5 TCID₅₀ of empty MVSchw or 20 µl of anti-CHIKV HMAF. The sera were diluted in a total volume of 100 µl in PBS before passive transfer at 24h and 16h before challenge with 100 pfu of CHIKV 06-49 strain, and then 12h post-challenge to mimic antibody persistence in infected animals. Mice mortality was analyzed for 2 weeks to determine protection.

Analysis of humoral immune responses. To evaluate the specific antibody responses, mice were bled via the periorbital route at different time after immunization. Sera were heat inactivated at 56°C for 30 min and anti-MV antibodies were detected by ELISA (ENZYGNOST-Siemens). HRP-conjugated anti-mouse immunoglobulin (Jackson Immuno Research) was used as secondary antibody. Anti-CHIKV antibodies were detected with a specific ELISA. Briefly, 96-wells plates were coated with a recombinant CHIKV-E2 protein produced in *E. Coli*. HRP-conjugated anti-mouse immunoglobulin was used as secondary antibody. The endpoint titers of pooled sera were calculated as the reciprocal of the last dilution giving twice the absorbance of sera from MV inoculated mice that served as negative controls. Anti-CHIKV neutralizing antibodies were measured by using a plaque reduction neutralization test (PRNT). Vero cells were seeded into 12-well plates for 24 h.

Serum samples were serially diluted in DMEM Glutamax/2% FCS. Dilutions of 100 μ l were incubated for 2 h at 37°C, under gentle agitation, with an equal volume of CHIKV containing 100 pfu of 06-49 strain. Remaining infectivity was then assayed on Vero cell monolayers overlaid with DMEM GlutaMAX™/2% FCS containing 0.8% final (wt/vol) carboxy methylcellulose. After 3 days of incubation, cells were fixed and stained with crystal violet for plaque count determination. The endpoint neutralization titer was calculated as the highest serum dilution tested that reduced the number of plaques by at least 50% (PRNT50).

Analysis of cell mediated immune response. Six-week-old CD46+/-IFN α /βR-/- mice were inoculated intraperitoneally with 10⁶ TCID50 of MV-CHIKV recombinant virus. Control mice were immunized with 10⁶ TCID50 of empty MV vector. Mice were euthanized at 7 days post-infection and spleens were collected. Splenocytes from immunized mice were incubated in RPMI, 10% FCS, and 10 IU of recombinant human interleukin-2 (rh-IL-2; Boehringer Mannheim). Their capacity to secrete IFN- γ upon stimulation was tested by enzyme-linked immunospot (ELISPOT) assay. Cells were stimulated 18h by concanavalin A (5 μ g/ml; Sigma) as a positive control, RPMI-IL-2 (10 U/ml) as a negative control, CHIKV (MOI 1), or MV (MOI 1). Multiscreen-HA 96-well plates were coated overnight at 4°C with 5 μ g of anti-mouse IFN- γ /ml (R4-6A2; Pharmingen) in PBS, washed, and then incubated with 100 μ l of RPMI and 10% FCS for 1 h at 37°C. The medium was replaced by 100 μ l of cell suspension (5x10⁵ splenocytes per well in triplicate) and 100 μ l of stimulating agent. After 2 h at 37°C, heated-FCS (10%) was added, and the plates were incubated for 18h at 37°C. After washing, biotinylated anti-mouse IFN- γ antibody (XMG1.2; Pharmingen) was added and the plates were incubated for 2 hours at room temperature. Streptavidin-alkaline phosphatase conjugate (Roche) was used as secondary step. Spots were developed with BCIP/ NBT (Promega) and counted (ELISpot Reader; Bio-Sys).

Expression of CHIKV virus-like particles by recombinant MV vector. CHIKV VLPs have been shown to elicit protective immunity against CHIKV infection (Akahata, W., *et al.*, A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. *Nat Med*, 2010. 16(3): p. 334-8). To benefit of this capacity, the inventors designed a recombinant MV vector able to

induce the secretion of CHIKV VLPs. To this aim, a cDNA encoding the C-E3-E2-6K-E1 structural proteins required for CHIKV VLPs production was chemically synthesized (Genscript) and optimized for measles virus expression in mammalian cells, then introduced into an additional transcription unit (ATU) of the Schwarz MV vaccine infectious cDNA (Figure 1). The recombinant MV-CHIKV virus was obtained by transfecting this plasmid into HEK-293 helper cells and propagation on Vero cells. Virus stocks were grown on Vero cells and titer was determined.

High amounts of CHIKV VLPs were secreted in the culture medium of infected cells, as demonstrated by immunofluorescence, western blot and electron microscopy.

This strategy provides a live recombinant MV vaccine virus secreting CHIKV VLPs at each round of replication. It was not expected that the assembly of native alphavirus particles would take place and that these VLPs would not hamper the simultaneous replication of a paramyxovirus. This is demonstrated here for the first time. Because MV vaccine is industrially produced as a crude viral extract, the batches of recombinant MV-CHIKV contain both live MV virus and non-replicating CHIKV VLPs. This strategy allows benefiting of the advantageous immunogenic property of multimeric antigens displayed on VLPs with no need of fastidious and expensive purification and concentration process. Moreover, no adjuvant is needed as the VLPs benefit of the advantageous immunogenic characteristics of live vaccines, such as balanced Th1 response and long-term memory.

The expression of CHIKV E2 and capsid antigens was demonstrated in infected Vero cells by immunofluorescence using a specific antibody (Mab 3E4) directed against the E2 protein of CHIKV (Figure 2). To look for the presence of secreted VLPs, the culture medium of infected cells was clarified by low-speed centrifugation, then layered onto a 20% sucrose cushion and concentrated by centrifugation at 41,000 rpm for 2 h in a SW41 rotor. Pellets were dissolved in PBS with 1% BSA. Proteins extracted from cell lysates and from concentrated culture media were fractionated by SDS-PAGE gel electrophoresis and transferred to cellulose membranes. The blots were probed with the 3E4 mouse Mab produced by hybridoma deposited at the CNCM (Collection Nationale de Cultures de Microorganismes, Paris, France) on September 6, 2007 under number I-3824, in the name of Institut Pasteur for the detection of E2 and an anti-capsid Mab (Figure 3).

The E2 protein was found both in cell lysates and in concentrated supernatant of infected cells at the correct size (46KDa), indicating the capacity of MV-CHIKV virus to induce the secretion of high-density particles containing the E2 protein. The capsid protein was also found in high-density particles, confirming the formation of CHIKV-VLPs. The presence of both C and E2 proteins in concentrated supernatant of infected cells suggests the formation of CHIKV VLPs. To observe their physical presence, the inventors analyzed by electron microscopy the pellets concentrated from supernatant of MV-CHIKV infected cells. The images revealed the presence of high amount of particles of size and morphology similar to those described after wild type CHIKV infection (Pletnev, S.V., *et al.*, Locations of carbohydrate sites on alphavirus glycoproteins show that E1 forms an icosahedral scaffold. *Cell*, 2001. 105(1): p. 127-36 ; Zhang, W., *et al.*, Placement of the structural proteins in Sindbis virus. *J Virol*, 2002. 76(22): p. 11645-58) (Figure 4). The observed particles present an external diameter of 65 nm and a core diameter of 40 nm. The surface organization indicates the presence of spikes on the surface of the VLPs, similarly arranged than for other alphaviruses (Pletnev, S.V., *et al.*, Locations of carbohydrate sites on alphavirus glycoproteins show that E1 forms an icosahedral scaffold. *Cell*, 2001. 105(1): p. 127-36 ; Zhang, W., *et al.*, Placement of the structural proteins in Sindbis virus. *J Virol*, 2002. 76(22): p. 11645-58). This observation confirms that infection of Vero cells by recombinant MV-CHIKV virus enables the secretion of high amounts of CHIK VLPs that self assemble.

The E2 protein was also expressed and secreted at the correct size (46KDa) by cells infected with Measles virus – sE2 Δ stem recombinant viruses, and Measles virus - CE3E26KE1 recombinant viruses.

Unfortunately, the analysis of MV-sE2 infected cells showed repeatedly the expression of a truncated form of the E2 protein. The inventors sequenced the E2 mRNA produced by MV-sE2 virus after RT-PCR amplification of infected cells. The analysis demonstrated the presence of a mutation generating a STOP codon, responsible for the truncation (Fig. 5).

The inventors then compared the replication rate of Measles Virus-sE2, Measles Virus-sE2 Δ stem, and Measles Virus-CE3E26KE1 recombinant viruses on Vero cells to standard Measles virus stock production, using a low MOI (0.01) (Fig. 6). The growth of MV-sE2 was similar to that of control MV. The growth of Measles virus-sE2 Δ stem and Measles virus-CE3E26KE1 recombinant viruses was slightly delayed, but their final titers were in the same range as that of empty Measles virus.

Immunogenicity of MV-sE2 and MV-CE3E26KE1 and protection in CD46-IFNAR mice.

CD46-IFNAR mice susceptible to MV infection were used to assess the immunogenicity of the recombinant MV-CHIKV viruses and their protective efficacy. These mice express the human CD46 gene with human-like tissue specificity and lack the type-I interferon receptors. Mice were housed under specific pathogen-free conditions at the Pasteur Institute animal facility and all experiments were approved and conducted in accordance with the guidelines of the Office of Laboratory Animal Care at Pasteur Institute. Six-week-old CD46-IFNAR mice were inoculated intraperitoneally (i.p.) with doses ranging from 10^3 to 10^5 TCID₅₀ of MV-CHIKV recombinant viruses and boosted 1 month later with the same dose of recombinant viruses. Control mice were immunized with the same dose of empty MVSchw vector. For antibody determination, blood samples were collected via the periorbital route 1 month after the first inoculation, then at 2 or 4 weeks after boosting.

Previous studies have shown that IFNAR mice are susceptible to lethal Chikungunya virus infection, showing pathological manifestations of infection and providing a model to evaluate immune mechanisms of protection (Couderc et al; 2008).

CD46-IFNAR mice susceptible to Measles virus infection were used to assess the immunogenicity of the recombinant Measles-Chikungunya viruses and their protective efficacy. These mice express the human CD46 gene with human-like tissue specificity and lack the type-I interferon receptors. Mice were housed under specific pathogen-free conditions at the Pasteur Institute animal facility and all experiments were approved and conducted in accordance with the guidelines of the Office of Laboratory Animal Care at Pasteur Institute.

Experiment 1 Analysis of the immunogenicity and the protective efficacy of Measles virus-CE3E26KE1 recombinant viruses in CD46-IFNAR mice.

- 5 Six-week-old CD46-IFNAR mice susceptible to Measles virus infection were intraperitoneally inoculated with 2.10^4 TCID₅₀ of Measles virus - Chikungunya virus recombinant viruses and boosted 1 month later with the same dose of recombinant viruses. Control mice were immunized with the same dose of empty Measles virus Schwarz vector (MV Schw). For antibody determination, blood samples were
- 10 collected via the periorbital route 1 month after the first inoculation, then at 2 weeks after boosting. Mice were then challenged by i.p. injection of 100 pfu of Chikungunya virus 06-49 strain for evaluating protection (Immunization and challenge schedule is given in figure 7).
- 15 To evaluate the specific antibody responses, mice were bled at different time-points after inoculation. Sera were heat inactivated at 56°C for 30 min and anti - Chikungunya virus antibodies were detected by ELISA. 96-well plates were coated with recombinant Chikungunya virus-E2 protein produced in *E. coli*. HRP-conjugated anti-mouse immunoglobulin was used as secondary antibody and mouse antibodies
- 20 anti-Chikungunya virus was used as a positive control. Anti-Chikungunya virus neutralizing antibodies were detected by a plaque reduction neutralization test (PRNT) (Warter L et al. JIM 2011 (D4 enclosed) and Russell PK et al. JIM 1967) on Vero cells using 50 PFU of Chikungunya virus-06-49 (produced on Vero cells). The endpoint titer was calculated as the highest serum dilution tested that reduced the
- 25 number of PFU by at least 50% (PRNT50) or 90% (PRNT90).

A single injection of Measles virus-CE3E26KE1 recombinant viruses induced high antibody titers, which were strongly boosted by a second injection (table1 – figure 8). After two immunizations, high neutralizing titers were induced (PRNT50 = 450-4050 and PRNT90 = 50-450). All animals immunized with 104 or 105 TCID₅₀ were

30 protected from CHIKV lethal challenge with 100 PFU of CHIKV-06-49, whereas immunization with the lower dose (103 TCID₅₀) protected 83% of the animals.

The CHIKV genome is an 11.8 kb, single-stranded RNA molecule of positive polarity. This virus is closely related to Semliki Forest virus (SFV), Sindbis virus (SINV), and other Old-World alphaviruses, and more distantly related to New-World alphaviruses like Venezuelan equine encephalitis virus (Griffin, D.E., *Alphaviruses*, in *Fields Virology*, 5th ed., D.M. Knipe, Editor 2007, Wolters Kluwer, Lippincott Williams & Wilkins. p. 1023-1067). The genomic RNA is capped, and directly translated into a full-length non-structural polyprotein (nsP) called P1234, which is encoded by the 5' two-thirds of the genome (Jose, J., J.E. Snyder, and R.J. Kuhn, A structural and functional perspective of alphavirus replication and assembly. *Future Microbiol*, 2009. 4(7): p. 837-56 ; Kuhn, R.J., *Togaviridae: the viruses and their replication*, in *Fields Virology*, 5th ed., D.M. Knipe, Editor 2007, Wolters Kluwer, Lippincott Williams & Wilkins. p. 1001-1022). This precursor cleaves itself to produce P123 and nsP4 that carries the RNA-dependent RNA polymerase activity. These proteins, together with cellular co-factors, assemble into a replication complex that produces antisense genomic RNA molecules. Subsequent cleavage of P123 into nsP1 and P23 gives rise to a polymerase complex making both sense and antisense genomic RNA. Further processing of P23 into nsP2 and nsP3 gives rise to a polymerase complex making only positive-sense genomic RNA molecules. In addition to replicating the viral genome, this viral protein complex transcribes a 26S subgenomic RNA from the 3' extremity of the viral genome. This messenger RNA is translated into a polyprotein precursor, which is cleaved by a combination of viral and cellular enzymes to produce a capsid protein (C), two major envelope proteins (E1 and E2), and two smaller accessory peptides, E3 and 6k. Once assembled, CHIKV virions are spherical particles of 65–70 nm in diameter, essentially composed of genomic RNA molecules associated with capsid proteins, and enveloped in a host-derived lipid membrane decorated by E1-E2 heterodimers organized in an icosahedral lattice (Voss, J.E., et al., Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. *Nature*, 2010. 468(7324): p. 709-12).

The disease severity, as much as the evolution and spread of the virus into new geographic areas are a serious health public matter that needs to be fixed. In order to solve this problem, vaccines with live attenuated virus, with chimeric alphavirus, with recombinant DNA or with virus-like particles have been developed.

Table 1. Antibody response of CD46-IFNAR mice to immunization with MV-sE2 and MV-CE3E26KE1 (determined in pooled mice sera)

	Elisa 1 dose	Elisa 2 dose	PRNT50	PRNT90
MV	<100	<100	<50	<50
MV-CHIK.sE2	450	4000	<50	<50
MV-CHIK.CE3E26KE1	4000	>12000	1350	150
Anti-CHIKV HMAF	ND	ND	4050	450

- 5 After two immunizations, high neutralizing titers were induced (PRNT50 = 1350 and PRNT90 = 150) that protected mice from a lethal challenge with 100 PFU of Chikungunya virus-06-49.

10 **Experiment 2 Analysis of the immunogenicity and the protective efficacy of a single dose of Measles virus-CE3E26KE1 recombinant virus in CD46-IFNAR mice.**

15 Six-week-old CD46-IFNAR mice were i.p. inoculated with 10^5 TCID₅₀ of Measles virus-CE3E26KE1 recombinant viruses. Control mice were immunized with the same dose of empty Measles virus Schw vector. Blood samples were collected via the periorbital route 2 weeks after immunization for antibody determination, and then mice were challenged by i.p. injection of 100 pfu of Chikungunya virus 06-49 (Immunization and challenge schedule is given in figure 9).

- 20 The Measles virus-CE3E26KE1 recombinant viruses induced high antibody titers after a single injection (table 2 – figure 10), and neutralizing titers that were sufficient to confer protection against a lethal challenge with 100 PFU of Chikungunya virus-06-49 in IFNAR mice.

25 **Table 2. Antibody response elicited in CD46-IFNAR mice after a single immunization with MV-CE3E26KE1 virus**

	MV Elisa titer	CHIKV Elisa titer	CHIKV PRNT50	CHIKV PRNT90
MV	10 000	<100	<50	<50
MV-CHIKV	10 000	4 050	150	50
Anti-CHIKV HMAF	ND	ND	12150	450

Experiment 3 Determination of the protective dose of Measles virus-CE3E26KE1 recombinant virus in CD46-IFNAR mice.

5

Six-week-old CD46-IFNAR mice were inoculated intraperitoneally (i.p.) with doses ranging from 10^3 to 10^5 TCID₅₀ of MV-CHIKV recombinant virus and boosted one month later with the same dose. Control mice were immunized with the same dose of empty MVSchw vector. One month after the last immunization, mice were challenged
 10 by i.p. injection of 100 pfu of CHIKV 06-49 (Immunization and challenge schedule is given in figure 11). For antibody determination, blood samples were collected via the periorbital route 1 month after the first inoculation, then 1 month after boosting, just before challenge. Specific Elisa's were performed to detect anti-MV and anti-CHIKV binding antibodies. Anti-CHIKV neutralizing antibodies titers were determined by a
 15 plaque reduction neutralization test (PRNT) on Vero cells.

The results are given in table 3 and figure 12.

Table 3. Antibody response after immunization with different doses of MV-CE3E26KE1

20

	1st immunisation				2 nd immunisation			
	MV Elisa titer	CHIKV Elisa titer	CHIKV PRNT50	CHIKV PRNT90	MV Elisa titer	CHIKV Elisa titer	CHIKV PRNT50	CHIKV PRNT90
MV 10^5	10 000	<100	<50	<50	300 000	<100	<50	<50
MV-CHIKV 10^3	1 000	1 350	50	<50	3 000	2 700	450	50
MV-CHIKV 10^4	3 000	4 050	150	50	30 000	12 150	1 350	150
MV-CHIKV-10^5	3 000	12 150	450	150	300 000	48 600	4 050	450

25 Both anti-MV and anti-CHIKV antibody titers increased when the dose of recombinant MV increased. A single immunization with MV-CE3E26KE1 virus induced high antibody titers, which were boosted by the second injection. After two immunizations, high neutralizing titers were induced (PRNT50 = 450-4050 and PRNT90 = 50-450). All animals immunized with 10^4 or 10^5 TCID₅₀ were protected
 30 from CHIKV lethal challenge with 100 PFU of CHIKV-06-49, whereas immunization with the lower dose (10^3 TCID₅₀) protected 83% of the animals (Figure 12).

Experiment 4 Evaluation of the protection conferred by passive transfer of sera from mice immunized with recombinant MV-CE3E26KE1 virus.

- 5 Six-week-old CD46-IFNAR mice were i.p. inoculated with 20 μ l of pooled sera from mice immunized with 10^5 TCID₅₀ of recombinant MV-CE3E26KE1. Control mice received either 20 μ l of pooled sera from mice immunized with 10^5 TCID₅₀ of empty Measles virus Schwarz or 20 μ l of anti-Chikungunya virus HMAF. The sera were diluted in a total volume of 100 μ l PBS. The sera were transferred at 24h and 16h
10 before challenge with 100 pfu of Chikungunya virus 06-49, and then 12h post-challenge to mimic antibody persistence in infected animals. Mice mortality was analyzed for 2 weeks to determine protection (Immunization and challenge schedule is given in figure 13).
- 15 Passive transfer of immune sera of mice immunized with MV-CE3E26KE1 virus protected 83% of recipient mice from lethal Chikungunya virus challenge, while mice that received anti-Chikungunya virus HMAF were fully protected. In contrast, mice that received immune sera from mice immunized with empty Measles viruses all died. These results indicate that humoral immune responses induced by Measles virus-
20 CE3E26KE1 recombinant viruses confer protection against Chikungunya virus infection in CD46-IFNAR mice (figure 14).

Experiment 5 Induction of specific cell-mediated immune responses.

- 25 To determine whether immunization with MV-CHIKV elicited cell-mediated immune responses, we measured by ELISPOT assay the capacity of splenocytes from immunized mice to secrete IFN- γ upon specific ex-vivo stimulation. Splenocytes were collected 7 days after a single immunization and both MV-specific and CHIKV-specific responses were evaluated. CHIKV and MV were used at an MOI of 1 for
30 splenocytes stimulation. A significant number of CHIKV-specific cells (up to 300/106 splenocytes, mean 150/106) were detected (Figure 15), which represents one third of MV-specific response in similar stimulation condition (up to 600/106 splenocytes, mean 500/106). All mice immunized with MV-CHKV, except one out of eight, had a significant CMI response to CHIKV. In contrast, control mice immunized with empty

MV-Schw had a similar MV-specific response but no CHIKV-specific response. These results show that a single inoculation of MV-CHIKV induced high levels of CHIKV- and MV-specific cellular immune response in the spleen of immunized mice.

5 **Experiment 6 Analysis of Measles virus pre-immunity impact on the immunogenicity and protective efficacy of recombinant MV-CE3E26KE1 virus in CD46-IFNAR mice.**

10 Six-week-old CD46-IFNAR mice were i.p. inoculated with $5 \cdot 10^3$ TCID₅₀ of empty Measles virus Schwarz (Group1 Figure 16) to mimic pre-immunity. Three months later, these mice were injected twice with 10^5 TCID₅₀ of Measles virus-CE3E26KE1 recombinant viruses at one month of interval. Control mice were immunized with 10^5 TCID₅₀ of Measles virus-CE3E26KE1 recombinant viruses (Group 2) or 10^5 TCID₅₀ of empty Measles virus Schw (Group 3). For antibody determination, blood samples
15 were collected via the periorbital route as indicated in Figure 16, and mice were then challenged by i.p. injection of 100 pfu of Chikungunya virus 06-49 strain for protection assays.

20 This experiment demonstrates that CD46-IFNAR mice previously immunized with $5 \cdot 10^3$ TCID₅₀ of empty Measles viruses are able to mount a protective Chikungunya virus immune response after immunization with Measles virus-CE3E26KE1 recombinant viruses. The ELISA and PRNT titers (Table 4 – figure 17) remain high and in the same range of that induced in naive mice (ELISA titer unchanged and PRNT titers reduced by one-fold dilution). 100% of the vaccinated animals were
25 protected from Chikungunya virus lethal challenge in both pre-immune and naive groups of animals immunized with Measles virus-CE3E26KE1 recombinant viruses.

Table 4. Antibody response of CD46-IFNAR mice to MV-CE3E26KE1 in the presence of pre-immunity to MV vector

30

Immunizations	1 st	2 nd				3 rd			
	MV Elisa	MV Elisa	CHIKV Elisa	CHIKV PRNT50	CHIKV PRNT90	MV Elisa	CHIKV Elisa	CHIKV PRNT50	CHIKV PRNT90
MV + MV-CHIKV	3 000	30 000	12 150	150	50	30 000	150 000	12 150	150
MV-CHIKV	ND	10 000	12 150	450	150	100 000	150 000	12 150	450
MV	ND	10 000	<50	<50	<50	100 000	<50	<50	<50

EXPERIENCE-7: Cross-reactivity of Abs elicited by vaccination

To determine whether immunization with MV-CHIKV elicited cross-reactive antibody response to different CHIKV primary isolates, sera obtained from animals of experiment 4 were tested for their ability to neutralize different CHIKV primary isolates. Four strains belonging to the ECSA genotype were chosen.

- CHIKV strain India, clinical isolate n° 3710 (NRC for Arbovirus, France), isolated in 2011. Passage 1 on Vero cells (December 2011), virus titer 6.3 log PFU/ml
- CHIKV strain Congo, clinical isolate n° 525 (NRC for Arbovirus, France), isolated in 2011. Passage 1 on Vero cells (June 2011), virus titer 6.5 log PFU/ml
- CHIKV strain Thailand, clinical isolate n° 1499 (NRC for Arbovirus, France), isolated in 2009. Passage on C6/36 cells (December, 2009), virus titer 6.3 log PFU/ml
- CHIKV strain La Réunion, clinical isolate 2006.49 (NRC for Arbovirus, France), isolated in 2006. Passage 3 on Vero cells (April 4th, 2011), virus titer 7.3 log PFU/ml

Anti-CHIKV neutralizing antibodies were detected by use of a plaque reduction neutralization test (PRNT). Vero cells were seeded into 12µwell plates for 24 h. Serum samples were serially diluted in DMEM Glutamax/2% FCS. Dilutions 100µl were incubated for 2 h at 37°C, under gentle agitation, with an equal volume of CHIKV containing 100 pfu of 06-49 strain. Remaining infectivity was then assayed on Vero cell monolayers overlaid with DMEM GlutaMAX/2% FCS containing 0.8% final (wt/vol) carboxy methylcellulose. After 3 days of incubation, cells were fixed and stained with crystal violet for plaque count determination. The endpoint neutralization titer was calculated as the highest serum dilution tested that reduced the number of plaques by at least 50% (PRNT₅₀).

Table 5. Cross-reactivity of neutralizing Ab from mice immunized with MV-CHIKV

	PRNT50 post 1st		PRNT50 post 2nd		PRNT50 post challenge	
	MV-CHIKV	MV	MV-CHIKV	MV	MV-CHIKV	MV
06-49	50	< 50	1350	< 50	450	ND
Inde	150	< 50	1350	< 50	13250	ND
Congo	< 50	< 50	1350	< 50	1350	ND
Thai	150	< 50	4050	< 50	12150	ND

The result shows that immunization of mice with MV-CHIKV induces cross-reactive antibodies that are able to neutralize several primary isolates of CHIKV from different countries. Interestingly, the challenge of animals with the 06-49 La Reunion virus results in even broadening the response and boosts the neutralization of Indian and Thai isolates to very strong levels. Only ECSA genotype was tested because of its availability at Institut Pasteur.

EXPERIENCE-8: Immunogenicity of MV-CHIKV in cynomolgus macaques

The immunogenicity of recombinant measles virus vaccine against Chikungunya was tested in non-human primates. Two groups of four cynomolgus macaques (*macaca fascicularis*) previously selected to be seronegative for flaviviruses and measles virus were vaccinated subcutaneously with 10^4 or 10^5 TCID₅₀ MV-CHIKV on day 0 then boosted on day 90 with the same dose. Serum and plasma were collected and stored at -20°C for later analysis. Neutralizing antibodies to Chikungunya virus were detected by using a PRNT assay.

Table 6.

Group	Animal	Code	Vaccine	Dose	Reciprocal CHIK-PRNT			
					Day 0	Day 21	Day 90	Day 111
D	D1	12/9	MV-CHIK	10^4	<10	574	<10	14
	D2	12/4	MV-CHIK	10^4	<10	142	73	97
	D3	12/5	MV-CHIK	10^4	<10	16	17	121
	D4	12/10	MV-CHIK	10^4	<10	70	83	118
E	E1	12/16	MV-CHIK	10^5	<10	247	101	382
	E2	12/23	MV-CHIK	10^5	<10	103	178	355
	E3	12/26	MV-CHIK	10^5	<10	6173	151	652
	E4	12/22	MV-CHIK	10^5	<10	97	386	228

Results presented in Table 6 show that all monkeys developed high titers of antibodies that neutralized CHIKV. The highest dose was more efficient than the lower dose. In most animals, boosting was efficient, as shown on figure 18 (day 90, the day of boost versus day 111, 21 days after boost). These results demonstrate the immunogenicity of MV-CHIKV vaccine candidate in non-human primates.

10 GENERAL CONCLUSION

The inventors have generated a recombinant MV-CHIK virus expressing stably the complete structural proteins CE3E26KE1 of CHIKV strain 06.49. Vero cells infected by this recombinant virus expressed high levels of CHIKV proteins and secreted high density VLPs. The recombinant virus was slightly delayed in growth kinetics but yielded similar titers that empty MV vector. Evaluated in CD46-IFNAR mice susceptible to MV infection, this vaccine candidate induced high levels of neutralizing antibodies to CHIKV depending on the dose and number of administrations (PRNT50

= 450-4050; PRNT90 = 150-450). All immunized mice were repeatedly protected, even after a single administration, demonstrating the strong immune capacity of this vaccine candidate. The passive transfer of immune sera in naïve animals conferred protection from lethal challenge, even in these highly susceptible mice. Lastly, the
5 inventors demonstrated that the presence of pre-existing immunity to MV vector in CD46-IFNAR mice did not prevent the induction of protective immunity after immunization with MV- CE3E26KE1 vaccine candidate. In view of the results, the recombinant vector thus obtained deserves to be evaluated in a reliable non-human primate model of infection.

A formalin inactivated vaccine was shown to be immunogenic in non-human primates and humans, but the high amount of antigen required for mass immunization that needs to be prepared under BSL-3 conditions is a limitation for the development of this strategy (Tiwari, M., et al., Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. (Vaccine, 2009. 27(18): p. 2513-22). The live attenuated TSI-GSD-218 CHIKV vaccine developed by the US-Army was immunogenic but caused side effects in Phase II clinical trials associated with reversion to virulence raising safety issues. Therefore, although the results obtained with vaccines based on live attenuated virus show that an efficient immunization can be achieved by this way, those vaccines are still questionable as there could be a risk of possibly side effects (Edelman R *et al.*, Am J Trop Med Hyg. 2000 Jun;62(6):681-685). Chimeric alphavirus vaccine strategies encoding the E1, E2 and capsid proteins from CHIKV are immunogenic in mice (Wang, E., et al., Chimeric alphavirus vaccine candidates for Chikungunya. Vaccine, 2008. 26(39): p. 5030-9), but the ability of alphavirus to easily recombine raises safety issues against the development of such strategies (Weaver, S.C., et al., Recombinational history and molecular evolution of western equine encephalomyelitis complex alphaviruses. J Virol, 1997. 71(1): p. 613-23).

Another strategy, which has been explored is to design recombinant DNA construct for use as a vaccine. DNA based CHIKV vaccines encoding the E1, E2 and capsid protein have been shown to be immunogenic in mice and non-human primates (Muthumani, K., et al., Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine, 2008. 26(40): p. 5128-34 ; Mallilankaraman, K., et al., A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis, 2011. 5(1): p. e928), but the DNA strategies do not induce the strong neutralizing immune response required for CHIKV clearance in humans. The disadvantages of DNA vaccines are that high quantities of DNA are required to induce an immune response and multiple booster vaccinations must be performed. The need for multiple boosts and high quantities of DNA injected into the nuclei of many cells raises concern regarding the fact that DNA vaccines can integrate into the host DNA and cause insertional mutagenesis. Therefore a recent study reports using DNA vaccines combined with live attenuated virus (WO2011/082388). Although this technique

allows reducing drawbacks of live attenuated virus and DNA vaccines, there is still a need in providing a vaccine with reduced side effects.

In order to avoid drawbacks of live attenuated virus and DNA vaccines, other types of vaccines have been developed such as vaccines based on virus-like particles (VLPs) which are obtained by expressing structural proteins of the Chikungunya virus. These structural proteins are able to self-assemble in virus-like particles. On that basis, vaccines comprising polynucleotides encoding all Chikungunya virus structural proteins have been worked out (Akahata, W., et al., A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med, 2010. 16(3): p. 334-8). However, VLPs produced *in vitro* are expensive to manufacture and require three administrations for a complete immunity, therefore these vaccines are not cheaply affordable. The CHIKV VLPs strategy disclosed in Akata *et al.* required several immunizations with an adjuvant to induce protection. For this reason, there is still a need for the design of improved vaccines that would enable the CHIKV VLPs to be generated *in vivo* in infected cells, in particular in infected cells of a host, and thus to provide an efficient and long-lasting immunity, especially which induces life-long immunity after only a single or two administration steps.

DESCRIPTION OF THE INVENTION

To this end, the inventors achieved the production of vaccines based on recombinant infectious replicative measles virus recombined with polynucleotides encoding Chikungunya virus antigens, which are recovered when the recombinant virus replicates in particular in the host after administration. The invention thus relates to a live CHIKV vaccine active ingredient based on the widely used Schwarz measles pediatric vaccine. In a preferred embodiment, this recombinant live MV-CHIKV vaccine yields CHIK virus-like particles by replicating in infected cells.

Measles virus is a non-segmented single-stranded, negative-sense enveloped RNA virus of the genus *Morbillivirus* within the family of *Paramyxoviridae*. This virus has been isolated in 1954 (Enders, J. F., and T. C. Peebles. 1954. Propagation in tissue cultures of cytopathogenic agents from patients with measles. Proc. Soc. Exp. Biol.

B09995A - SQL - eolf-seq1
SEQUENCE LISTING

<110> INSTITUT PASTEUR
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
THEMIS BIOSCIENCE GMBH

<120> RECOMBINANT MEASLES VIRUS EXPRESSING CHIKUNGUNYA VIRUS
POLYPEPTIDES AND THEIR APPLICATIONS

<130> B09995A - AD/DP/AM

<140> PCT/ EP XXXXXXXX
<141> 2013-09-26

<150> EP 12306176.4
<151> 2012-09-27

<160> 33

<170> PatentIn version 3.5

<210> 1
<211> 18967
<212> DNA
<213> Artificial Sequence

<220>
<223> pTM-MV Schw (GenBank: FW366202.1)

<400> 1
gcggccgcta atacgactca ctatagggcc aactttgttt ggtctgatga gtccgtgagg 60
acgaaacccg gagtcccggg tcaccaaaca aagttgggta aggatagttc aatcaatgat 120
catcttctag tgcacttagg attcaagatc ctattatcag ggacaagagc aggattaggg 180
atatccgaga tggccacact ttttaaggagc ttagcattgt tcaaaagaaa caaggacaaa 240
ccaccatta catcaggatc cggtaggagc atcagaggaa tcaaacacat tattatagta 300
ccaatccctg gagattcctc aattaccact cgatccagac ttctggaccg gttggtagg 360
ttaattggaa acccgatgt gagcggggcc aaactaacag gggcactaat aggtatatta 420
tccttatttg tggagtctcc aggtcaattg attcagagga tcaccgatga ccctgacgtt 480
agcataaggc tgtagaggt tgtccagagt gaccagtcac aatctggcct taccttcgca 540
tcaagaggta ccaacatgga ggatgaggcg gaccaatact ttccacatga tgatccaatt 600
agtagtgatc aatccagggt cggtatggtc gggaacaagg aaatctcaga tattgaagtg 660
caagaccctg agggattcaa catgattctg ggtaccatcc tagcccaaatt ttgggtcttg 720
ctcgcaaagg cggttacggc ccagacacg gcagctgatt cggagctaag aaggtaggata 780
aagtacacc acaaagaag ggtagttagt gaatttagat tggagagaaa atggttgat 840
gtggtgagga acaggattgc cgaggacctc tccttacgcc gattcatggt cgctctaata 900
ctggatatca agagaacacc cggaacaaa ccaggattg ctgaaatgat atgtgacatt 960
gatacatata tcgtagaggc aggattagcc agttttatcc tgactattaa gtttgggata 1020

06/27/2018 10:02 00407

2013-09-26 09:23

INSTITUT PASTEUR

B09995A - SQL - eof-seq1

gaaactatgt atcctgctct tggactgcat gaatttgctg gtgagttatc cacacttgag 1080
 tccttgatga acctttacca gcaaatgggg gaaactgcac cctacatggt aatcctggag 1140
 aactcaattc agaacaagtt cagtgcagga tcataccctc tgctctggag ctatgccatg 1200
 ggagtaggag tggaaacttga aaactccatg ggaggtttga actttggccg atcttacttt 1260
 gatccagcat atttttagatt agggcaagag atggtaagga ggtcagctgg aaaggtcagt 1320
 tccacattgg catctgaact cggtatcact gccgaggatg caaggcttgt ttcagagatt 1380
 gcaatgcata ctactgagga caagatcagt agagcgggtg gaccagaca agcccaagta 1440
 tcatttctac acggtgatca aagtgagaat gagctaccga gattgggggg caaggaagat 1500
 aggagggtca aacagagtcg aggagaagcc agggagagct acagagaaac cggggcccagc 1560
 agagcaagtg atgcgagagc tgcccatctt ccaaccggca caccctaga cattgacact 1620
 gcaacggagt ccagccaaga tccgcaggac agtcgaaggt cagctgacgc cctgcttagg 1680
 ctgcaagcca tggcaggaat ctcggaagaa caaggctcag acacggacac ccctatagtg 1740
 tacaatgaca gaaatcttct agactagggt cgagaggccg agggccagaa caacatccgc 1800
 ctaccatcca tcattgttat aaaaaactta ggaaccaggt ccacacagcc gccagcccat 1860
 caaccatcca ctcccacgat tggagccaat ggcagaagag caggcacgcc atgtcaaaaa 1920
 cggactggaa tgcattccgg ctctcaaggc cgagcccatc ggctcactgg ccatcgagga 1980
 agctatggca gcatggtcag aaatatcaga caaccagga caggagcgag ccacctgcag 2040
 ggaagagaag gcaggcagtt cgggtctcag caaacatgc ctctcagaa ttggatcaac 2100
 tgaaggcggg gcacctcgca tccgcggta gggacctgga gagagcgatg acgacgctga 2160
 aactttggga atcccccaa gaaatctcca ggcataagc actgggttac agtggtatta 2220
 cgtttatgat cacagcgggtg aagcgggtta ggaatccaa gatgctgact ctatcatggt 2280
 tcaatcaggc cttgatgggt atagcaccct ctgaggagga gacaatgaat ctgaaaacag 2340
 cgatgtggat attggcgaac ctgataccga gggatatgct atcactgacc ggggatctgc 2400
 tcccatctct atgggggttca gggcttctga tgttgaaact gcagaaggag gggagatcca 2460
 cgagctcctg agactccaat ccagaggcaa caactttccg aagcttggga aaactctcaa 2520
 tgttcctccg cccccggacc ccggtagggc cagcacttcc gggacacca ttaaaaaggg 2580
 cacagacgag agattagcct catttggaac ggagatcgcg tctttattga cagggtggtgc 2640
 aacccaatgt gctcgaaagt caccctcgga accatcaggg ccagggtgcac ctgcggggaa 2700
 tgtccccgag tgtgtgagca atgccgact gatacaggag tggacaccgg aatctggtac 2760
 cacaatctcc ccgagatccc agaataatga agaaggggga gactattatg atgatgagct 2820
 gttctctgat gtccaagata ttaaaacagc cttggccaaa atacacgagg ataatacagaa 2880

B09995A - SQL - eof-seq1

gataatctcc aagctagaat cactgctggtt attgaagga gaagttgagt caattaagaa	2940
gcagatcaac aggcaaaata tcagcatatc caccctggaa ggacacctct caagcatcat	3000
gatcgccatt cctggacttg ggaaggatcc caacgacccc actgcagatg tcgaaatcaa	3060
tcccgacttg aaacccatca taggcagaga ttcaggccga gcaactggccg aagttctcaa	3120
gaaacccgtt gccagccgac aactccaagg aatgacaaat ggacggacca gttccagagg	3180
acagctgctg aaggaatttc agctaaagcc gatcgggaaa aagatgagct cagccgtcgg	3240
gtttgttcct gacaccggcc ctgcatcacg cagtgtaatc cgctccatta taaaatccag	3300
ccggctagag gaggatcgga agcgttacct gatgactctc cttgatgata tcaaaggagc	3360
caatgatctt gccaaagtcc accagatgct gatgaagata ataatgaagt agctacagct	3420
caacttacct gccaacccca tgccagtcga cccaactagt acaacctaaa tccattataa	3480
aaaacttagg agcaaagtga ttgcctcca aggtccacaa tgacagagac ctacgacttc	3540
gacaagtcgg catgggacat caaagggtcg atcgctccga tacaaccac cacctacagt	3600
gatggcaggc tgggtgcccc ggtcagagtc atagatcctg gtctaggcga caggaaggat	3660
gaatgcttta tgtacatgtt tctgctgggg gttgttgagg acagcgattc cctagggcct	3720
ccaatcgggc gagcatttgg gttcctgccc ttaggtgttg gcagatccac agcaaagccc	3780
gaaaaactcc tcaaagaggc cactgagctt gacatagttg ttagacgtac agcagggtc	3840
aatgaaaaac tgggtgttcta caacaacacc ccactaactc tcctcacacc ttggagaaag	3900
gtcctaacia cagggagtggt cttcaacgca aaccaagtgt gcaatgcggt taatctgata	3960
ccgctcgata ccccgagag gttccgtgtt gtttatatga gcatcaccg tctttcggat	4020
aacgggtatt acaccgttcc tagaagaatg ctggaattca gatcgggtcaa tgcagtggcc	4080
ttcaacctgc tgggtgaccct taggattgac aaggcgatag gccctgggaa gatcatcgac	4140
aatacagagc aacttcctga ggcaacattt atggtccaca tcgggaactt caggagaaag	4200
aagagtgaag tctactctgc cgattattgc aaaatgaaaa tcgaaaagat gggcctggtt	4260
tttgacttg gtgggatagg gggcaccagt cttcacatta gaagcacagg caaatgagc	4320
aagactctcc atgcacaact cgggttcaag aagaccttat gttaccgct gatggatatc	4380
aatgaagacc ttaatcgatt actctggagg agcagatgca agatagtaag aatccaggca	4440
gttttgagc catcagttcc tcaagaattc cgcatttacg acgacgtgat cataaatgat	4500
gaccaaggac tattcaaagt tctgtagacc gtagtgccca gcaatgccg aaaacgaccc	4560
ccctcacaat gacagccaga aggcccggac aaaaaagccc cctccgaaag actccacgga	4620
ccaagcgaga ggccagccag cagccgacgg caagcgcgaa caccaggcgg cccagcaca	4680
gaacagccct gacacaaggc caccaccagc caccccaatc tgcactctcc tcgtgggacc	4740
cccagggacc aacccccaaag gctgcccccg atccaaacca ccaaccgcat ccccaccacc	4800

B09995A - SQL - eolf-seql

cccgggaaag aaacccccag caattggaag gcccctcccc ctcttcctca acacaagaac	4860
tccacaaccg aaccgcacaa gcgaccgagg tgaccaacc gcaggcatcc gactccctag	4920
acagatcctc tctccccggc aaactaaaca aaacttaggg ccaaggaaca tacacacca	4980
acagaaccca gacccccggc cacggcgccg cgcccccaac ccccgacaac cagagggagc	5040
ccccaaccaa tcccgccggc tcccccggtg cccacaggca gggacacaa cccccgaaca	5100
gacccagcac ccaaccatcg acaatccaag acggggggggc cccccaaaa aaaggcccc	5160
aggggcccag agccagcacc gcgagggaagc ccacccaccc cacacacgac cacggcaacc	5220
aaaccagaac ccagaccacc ctgggcccacc agtctccaga ctcggccatc accccgcaga	5280
aaggaaaggc cacaacccgc gcaccccagc cccgatccgg cggggagcca cccaacccga	5340
accagcacc aagagcgatc cccgaaggac ccccgaaaccg caaaggacat cagtatccca	5400
cagcctctcc aagtcccccg gtctcctcct cttctcgaag ggacaaaaag atcaatccac	5460
cacacccgac gacactcaac tccccacccc taaaggagac accgggaatc ccagaatcaa	5520
gactcatcca atgtccatca tgggtctcaa ggtgaacgtc tctgccatat tcatggcagt	5580
actgttaact ctccaaacac ccaccggtca aatccattgg ggcaatctct ctaagatagg	5640
ggtggtagga ataggaagtg caagctacaa agttatgact cgttccagcc atcaatcatt	5700
agtcataaaa ttaatgcca atataactct cctcaataac tgcacgaggg tagagattgc	5760
agaatacagg agactactga gaacagtttt ggaaccaatt agagatgcac ttaatgcaat	5820
gacccagaat ataagaccgg ttcagagtgt agcttcaagt aggagacaca agagatttgc	5880
gggagtagtc ctggcagggtg cggccctagg cgttgccaca gctgctcaga taacagccgg	5940
cattgcactt caccagtcca tgctgaactc tcaagccatc gacaatctga gagcgagcct	6000
ggaaactact aatcaggcaa ttgagacaat cagacaagca gggcaggaga tgatattggc	6060
tgttcagggt gtccaagact acatcaataa tgagctgata ccgtctatga accaactatc	6120
ttgtgattta atcggccaga agctcgggct caaattgctc agatactata cagaaatcct	6180
gtcattatth ggccccagtt tacgggaccc catatctgcg gagatatcta tccaggcttt	6240
gagctatgcg ctgggaggag acatcaataa ggtgttagaa aagctcggat acagtggagg	6300
tgatttactg ggcattctag agagcggagg aataaaggcc cgataactc acgtcgacac	6360
agagtcctac ttcattgtcc tcagtatagc ctatccgacg ctgtccgaga ttaaggggggt	6420
gattgtccac cggctagagg gggctctcgt caacataggc tctcaagagt ggtataccac	6480
tgtgccaag tatgttgcaa cccaagggtg ccttatctcg aattttgatg agtcatcgtg	6540
tactttcatg ccagagggga ctgtgtgcag ccaaaatgcc ttgtacccga tgagtctct	6600
gtccaagaa tgcctccggg ggtacaccaa gtcctgtgct cgtacactcg tatccgggtc	6660

B09995A - SQL - eof-seq1

ttttgggaac	cggttcattt	tatcacaagg	gaacctaata	gccaatgtg	catcaatcct	6720
ttgcaagtgt	tacacaacag	gaacgatcat	taatcaagac	cctgacaaga	tcctaacata	6780
cattgctgcc	gatcactgcc	cggtagtcga	ggtgaacggc	gtgaccatcc	aagtcgggag	6840
caggaggtat	ccagacgctg	tgtacttgca	cagaattgac	ctcggtcctc	ccatatcatt	6900
ggagaggttg	gacgtaggga	caaatctggg	gaatgcaatt	gctaagttgg	aggatgccaa	6960
ggaattgttg	gagtcatcgg	accagatatt	gaggagtatg	aaaggtttat	cgagcactag	7020
catagtctac	atcctgattg	cagtgtgtct	tggagggttg	atagggatcc	ccgctttaat	7080
atgttgctgc	agggggcggt	gtaacaaaaa	gggagaacaa	gttggtatgt	caagaccagg	7140
cctaaagcct	gatcttacgg	gaacatcaaa	atcctatgta	aggtcgctct	gatcctctac	7200
aactcttgaa	acacaaatgt	cccacaagtc	tcctcttcgt	catcaagcaa	ccaccgcacc	7260
cagcatcaag	cccacctgaa	attatctccg	gcttccctct	ggccgaacaa	tatcggtagt	7320
taatcaaaac	ttaggggtgca	agatcatcca	caatgtcacc	acaacgagac	cggataaatg	7380
ccttctacaa	agataacccc	catcccaagg	gaagtaggat	agtcattaac	agagaacatc	7440
ttatgattga	tagaccttat	gttttgctgg	ctgttctgtt	tgtcatgttt	ctgagcttga	7500
tcgggttgct	agccattgca	ggcattagac	ttcatcgggc	agccatctac	accgcagaga	7560
tccataaaag	cctcagcacc	aatctagatg	taactaactc	aatcgagcat	cagggtcaagg	7620
acgtgctgac	accactcttc	aaaatcatcg	gtgatgaagt	gggcctgagg	acacctcaga	7680
gattcactga	cctagtgaag	ttaatctctg	acaagattaa	attccttaat	ccggataggg	7740
agtacgactt	cagagatctc	acttggtgta	tcaaccgccc	agagagaatc	aaattggatt	7800
atgatcaata	ctgtgcagat	gtggctgctg	aagagctcat	gaatgcattg	gtgaactcaa	7860
cttactgga	gaccagaaca	accaatcagt	tcctagctgt	ctcaaaggga	aactgctcag	7920
ggcccactac	aatcagaggt	caattctcaa	acatgtcgct	gtccctgtta	gacttgtatt	7980
taggtcgagg	ttacaatgtg	tcattctatag	tcactatgac	atcccaggga	atgtatgggg	8040
gaacttacct	agtggaaaag	cctaactctga	gcagcaaaaag	gtcagagttg	tcacaactga	8100
gcatgtaccg	agtgtttgaa	gtaggtgtta	tcagaaatcc	gggtttgggg	gctccggtgt	8160
tccatatgac	aaactatctt	gagcaaccag	tcagtaatga	tctcagcaac	tgtatggtgg	8220
ctttggggga	gctcaaactc	gcagcccttt	gtcacgggga	agattctatc	acaattccct	8280
atcagggatc	agggaaaggt	gtcagcttcc	agctcgtcaa	gctaggtgtc	tggaaatccc	8340
caaccgacat	gcaatcctgg	gtcccccttat	caacggatga	tccagtgata	gacaggcttt	8400
acctctcatc	tcacagaggt	gttatcgctg	acaatcaagc	aaaatgggct	gtcccgacaa	8460
cacgaacaga	tgacaagttg	cgaatggaga	catgcttcca	acaggcgtgt	aagggtaaaa	8520
tccaagcact	ctgcgagaat	cccagtgagg	caccattgaa	ggataacagg	attccttcatt	8580

B09995A - SQL - eof-seq1

acggggtctt	gtctgttgat	ctgagtctga	cagttgagct	taaaatcaaa	attgcttcgg	8640
gattcgggcc	attgatcaca	cacggttcag	ggatggacct	atacaaatcc	aaccacaaca	8700
atgtgtattg	gctgactatc	ccgccaatga	agaacctagc	cttaggtgta	atcaacacat	8760
tggagtggat	accgagattc	aaggttagtc	cctacctctt	cactgtccca	attaaggaag	8820
caggcgaaga	ctgccatgcc	ccaacatacc	tacctgcgga	ggtggatggt	gatgtcaaac	8880
tcagttccaa	tctgggtgatt	ctacctggtc	aagatctcca	atatgttttg	gcaacctacg	8940
atacttccag	ggttgaacat	gctgtggttt	attacgttta	cagcccaagc	cgctcatttt	9000
cttactttta	tccttttagg	ttgcctataa	agggggtccc	catcgaatta	caagtggaat	9060
gcttcacatg	ggacaaaaa	ctctgggtgcc	gtcacttctg	tgtgcttgcg	gactcagaat	9120
ctgggtggaca	tatcactcac	tctgggatgg	tgggcatggg	agtcagctgc	acagtcaccc	9180
gggaagatgg	aaccaatcgc	agatagggct	gctagtgaac	caatcacatg	atgtcaccca	9240
gacatcaggc	ataccacta	gtgtgaaata	gacatcagaa	ttaagaaaaa	cgtaggggtcc	9300
aagtggttcc	ccgttatgga	ctcgtatct	gtcaaccaga	tcttataccc	tgaagttcac	9360
ctagatagcc	cgatagttac	caataagata	gtagccatcc	tggagtatgc	tcgagtcctt	9420
cacgcttaca	gcctggagga	ccctacactg	tgtcagaaca	tcaagcaccg	cctaaaaaac	9480
ggattttcca	accaaataat	tataaacaat	gtggaagttg	ggaatgtcat	caagtccaag	9540
cttaggagtt	atccggccca	ctctcatatt	ccatatccaa	attgtaatca	ggattttattt	9600
aacatagaag	acaaagagtc	aacgaggaag	atccgtgaac	tcctcaaaaa	ggggaattcg	9660
ctgtactcca	aagtcagtga	taaggttttc	caatgcttaa	gggacactaa	ctcacggctt	9720
ggcctaggct	ccgaattgag	ggaggacatc	aaggagaaag	ttattaactt	gggagttttac	9780
atgcacagct	cccagtgggt	tgagcccttt	ctgttttggt	ttacagtcaa	gactgagatg	9840
aggtcagtga	ttaaatcaca	aaccataact	tgccatagga	ggagacacac	acctgtattc	9900
ttcactggta	gttcagttga	gttgctaate	tctcgtgacc	ttgttgctat	aatcagtaaa	9960
gagtctcaac	atgtatatta	cctgacattt	gaactggttt	tgatgtattg	tgatgtcata	10020
gaggggaggt	taatgacaga	gaccgctatg	actattgatg	ctaggtatac	agagcttcta	10080
ggaagagtca	gatacatgtg	gaaactgata	gatggtttct	tcctgcact	cggaatcca	10140
acttatcaaa	ttgtagccat	gctggagcct	ctttcacttg	cttacctgca	gctgagggat	10200
ataacagtag	aactcagagg	tgctttcctt	aaccactgct	ttactgaaat	acatgatgtt	10260
cttgacaaaa	acgggttttc	tgatgaaggt	acttatcatg	agttaactga	agctctagat	10320
tacattttca	taactgatga	catacatctg	acaggggaga	ttttctcatt	tttcagaagt	10380
ttcggccacc	ccagacttga	agcagtaacg	gctgctgaaa	atgttaggaa	atacatgaat	10440

Med. 86:277-286.), and live attenuated vaccines have been derived from this virus since then to provide vaccine strains and in particular from the Schwarz strain. Measles vaccines have been administered to hundreds of millions of children over the last 30 years and have proved its efficiency and safety. It is produced on a large scale in many countries and is distributed at low cost. For all these reasons, the inventors used attenuated Measles viruses to generate recombinant Measles virus particles stably expressing structural antigens of Chikungunya virus, in particular as VLPs.

The invention thus relates to a nucleic acid construct which comprises a polynucleotide encoding at least one Chikungunya virus (CHIKV) structural protein said polynucleotide being operably linked, in particular cloned into a cDNA molecule which encodes the nucleotide sequence of the full-length, infectious antigenomic (+) RNA strand of a measles virus (MV).

A nucleic acid construct according to the invention is in particular a purified DNA molecule, obtained or obtainable by recombination of various polynucleotides of different origins, operably linked together.

The expression "operably linked" refers to the functional link existing between the different polynucleotides of the nucleic acid construct of the invention such that said different polynucleotides and nucleic acid construct are efficiently transcribed and if appropriate translated, in particular in cells or cell lines, especially in cells or cell lines used as part of a rescue system for the production of chimeric infectious MV particles of the invention or in host cells.

In a particular embodiment of the invention, the construct is prepared by cloning a polynucleotide encoding one structural protein or a plurality of structural proteins of CHIKV in the cDNA encoding the full-length antigenomic (+) RNA of the measles virus. Alternatively, a nucleic acid construct of the invention may be prepared using steps of synthesis of nucleic acid fragments or polymerization from a template, including by PCR.

B09995A - SQL - eolf-seq1

cagcctaaag tcattgtgta tgagactctg atgaaaggctc atgccatatt ttgtggaatc	10500
ataatcaacg gctatcgtga caggcacgga ggcagttggc caccgctgac cctccccctg	10560
catgctgcag acacaatccg gaatgctcaa gcttcagggtg aagggttaac acatgagcag	10620
tgcgttgata actggaaatc ttttgctgga gtgaaatttg gctgctttat gcctcttagc	10680
ctggatagtg atctgacaat gtacctaaag gacaaggcac ttgctgctct ccaaagggaa	10740
tgggattcag tttacccgaa agagttcctg cgttacgacc ctcccaaggg aaccgggtca	10800
cggaggcttg tagatgtttt ccttaatgat tcgagctttg acccatatga tgtgataatg	10860
tatgttgtaa gtggagctta cctccatgac cctgagttca acctgtctta cagcctgaaa	10920
gaaaaggaga tcaaggaaac aggtagactt tttgctaaaa tgacttacia aatgagggca	10980
tgccaagtga ttgctgaaaa tctaattctca aacgggattg gcaaataatt taaggacaat	11040
gggatggcca aggatgagca cgatttgact aaggcactcc acactctagc tgtctcagga	11100
gtccccaag atctcaaaga aagtcacagg ggggggcccag tcttaaaaac ctactcccga	11160
agcccagtc acacaagtac caggaaactg agagcagcaa aagggtttat agggttccct	11220
caagtaattc ggcaggacca agacactgat catccggaga atatggaagc ttacgagaca	11280
gtcagtgcat ttatcacgac tgatctcaag aagtactgcc ttaattggag atatgagacc	11340
atcagcttgt ttgcacagag gctaaatgag atttacggat tgccctcatt tttccagtgg	11400
ctgcataaga ggcttgagac ctctgtcctg tatgtaagt accctcattg ccccccgac	11460
cttgacgccc atatcccgtt atataaaagtc cccaatgatc aaatcttcat taagtaccct	11520
atgggaggta tagaagggtg ttgtcagaag ctgtggacca tcagcaccat tccctatcta	11580
tacctggctg cttatgagag cggagtaagg attgcttcgt tagtgcaagg ggacaatcag	11640
accatagccg taacaaaaag ggtacccagc acatggccct acaacctta gaaacgggaa	11700
gctgctagag taactagaga ttactttgta attcttaggc aaaggctaca tgatattggc	11760
catcacctca aggc aaatga gacaattgtt tcatcacatt tttttgtcta ttcaaaagga	11820
atatattatg atgggctact tgtgtcccaa tcactcaaga gcatcgcaag atgtgtattc	11880
tggtcagaga ctatagttga tgaaacaagg gcagcatgca gtaatattgc tacaacaatg	11940
gctaaaagca tcgagagagg ttatgaccgt taccttgcat attccctgaa cgtcctaaaa	12000
gtgatacagc aaattctgat ctctcttggc ttcacaatca attcaaccat gaccgggat	12060
gtagtcatac cctcctcac aaacaacgac ctcttaataa ggatggcact gttgcccgt	12120
cctattgggg ggatgaatta tctgaatatg agcaggctgt ttgtcagaaa catcggtgat	12180
ccagtaacat catcaattgc tgatctcaag agaattgatt tcgcctcact aatgcctgaa	12240
gagaccctcc atcaagtaat gacacaacaa ccgggggact cttcattcct agactgggct	12300
agcgaccctt actcagcaaa tcttgtatgt gtccagagca tcactagact cctcaagaac	12360

B09995A - SQL - eolf-seq1

ataactgcaa	ggtttgtcct	gatccatagt	ccaaacccaa	tgttaaaagg	attattccat	12420
gatgacagta	aagaagagga	cgagggactg	gcggcattcc	tcattggacag	gcatattata	12480
gtacctaggg	cagctcatga	aatcctggat	catagtgtca	caggggcaag	agagtctatt	12540
gcaggcatgc	tgataaccac	aaaaggcttg	attcgagcca	gcatgaggaa	gggggggtta	12600
acctctcgag	tgataaccag	attgtccaat	tatgactatg	aacaattcag	agcagggatg	12660
gtgctattga	caggaagaaa	gagaaatgtc	ctcattgaca	aagagtcatt	ttcagtgacg	12720
ctggcgagag	ctctaagaag	ccatatgtgg	gcgaggctag	ctcgaggacg	gcctattttac	12780
ggccttgagg	tccctgatgt	actagaatct	atgcgaggcc	accttattcg	gcgtcatgag	12840
acatgtgtca	tctgcgagtg	tggatcagtc	aactacggat	ggttttttgt	cccctcgggt	12900
tgccaactgg	atgatattga	caaggaaaca	tcattcctga	gagtcaccata	tattggttct	12960
accactgatg	agagaacaga	catgaagctt	gccttcgtaa	gagccccaag	tcgatccttg	13020
cgatctgctg	ttagaatagc	aacagtgtac	tcattgggctt	acggtgatga	tgatagctct	13080
tggaacgaag	cctggttggt	ggctaggcaa	agggccaatg	tgagcctgga	ggagctaagg	13140
gtgatcactc	ccatctcaac	ttcgactaat	ttagcgcata	ggttgagggg	tcgtagcact	13200
caagtgaat	actcaggtag	atcccttgct	cgagtggcga	ggtataccac	aatctccaac	13260
gacaatctct	catttgctcat	atcagataag	aagggttgata	ctaactttat	ataccaacaa	13320
ggaatgcttc	taggggttggg	tgtttttagaa	acattgtttc	gactcgagaa	agataaccgga	13380
tcattctaaca	cggtattaca	tcttcacgtc	gaaacagatt	gttgctgat	cccgatgata	13440
gatcatccca	ggatacccag	ctcccgaag	ctagagctga	gggcagagct	atgtaccaac	13500
ccattgatat	atgataatgc	acctttaatt	gacagagatg	caacaaggct	atacaccag	13560
agccatagga	ggcaccttgt	ggaatttggt	acatggtcca	cacccaact	atatcacatt	13620
ttagctaagt	ccacagcact	atctatgatt	gacctggtaa	caaaatttga	gaaggaccat	13680
atgaatgaaa	tttcagctct	cataggggat	gacgatatca	atagtttcat	aactgagttt	13740
ctgctcatag	agccaagatt	attcactatc	tacttgggcc	agtgtgcggc	catcaattgg	13800
gcatttgatg	tacattatca	tagaccatca	gggaaatatc	agatgggtga	gctgttgctca	13860
tcgttccttt	ctagaatgag	caaaggagtg	tttaagggtgc	ttgtcaatgc	tctaagccac	13920
ccaaagatct	acaagaaatt	ctggcattgt	ggtattatag	agcctatcca	tggtccttca	13980
cttgatgctc	aaaacttgca	cacaactgtg	tgcaacatgg	tttacacatg	ctatatgacc	14040
tacctcgacc	tggtgttgaa	tgaagagtta	gaagagttca	catttctctt	gtgtgaaagc	14100
gacgaggatg	tagtaccgga	cagattcgac	aacatccagg	caaaacactt	atgtgttctg	14160
gcagatttgt	actgtcaacc	agggacctgc	ccaccaattc	gaggtctaag	accggtagag	14220

B09995A - SQL - eof-seq1

aaatgtgcag	ttctaaccga	ccatatcaag	gcagaggcta	tgttatctcc	agcaggatct	14280
tcgtggaaca	taaatccaat	tattgtagac	cattactcat	gctctctgac	ttatctccgg	14340
cgaggatcga	tcaaacagat	aagattgaga	gttgatccag	gattcatttt	cgacgccctc	14400
gctgaggtaa	atgtcagtca	gccaaagatc	ggcagcaaca	acatctcaaa	tatgagcatc	14460
aaggctttca	gacccccaca	cgatgatgtt	gcaaaattgc	tcaaagatat	caacacaagc	14520
aagcacaatc	ttccccatttc	aggggggcaat	ctcgccaatt	atgaaatcca	tgctttccgc	14580
agaatcgggt	tgaactcatc	tgcttgctac	aaagctgttg	agatatcaac	attaattagg	14640
agatgccttg	agccagggga	ggacggcttg	ttcttggttg	agggatcggg	ttctatgttg	14700
atcacttata	aagagatact	taaactaaac	aagtgtttct	ataatagtgg	ggtttccgcc	14760
aattctagat	ctggtcaaag	ggaattagca	ccctatccct	ccgaagttgg	ccttgctgaa	14820
cacagaatgg	gagtaggtaa	tattgtcaaa	gtgctcttta	acgggaggcc	cgaagtcacg	14880
tgggtaggca	gtgtagattg	cttcaatttc	atagttagta	atatccctac	ctctagtgtg	14940
gggtttatcc	attcagatat	agagaccttg	cctgacaaag	atactataga	gaagctagag	15000
gaattggcag	ccatcttatc	gatggctctg	ctcctgggca	aaataggatc	aatactggtg	15060
attaagctta	tgcctttcag	cggggatttt	gttcagggat	ttataagtta	tgtagggctc	15120
cattatagag	aagtgaacct	tgtataccct	agatacagca	acttcatctc	tactgaatct	15180
tatttggtta	tgacagatct	caaggctaac	cggctaata	atcctgaaaa	gattaagcag	15240
cagataattg	aatcatctgt	gaggacttca	cctggactta	taggtcacat	cctatccatt	15300
aagcaactaa	gctgcataca	agcaattgtg	ggagacgcag	ttagtagagg	tgatatcaat	15360
cctactctga	aaaaacttac	acctatagag	caggtgctga	tcaattgcgg	gttggcaatt	15420
aacggaccta	agctgtgcaa	agaattgatc	caccatgatg	ttgcctcagg	gcaagatgga	15480
ttgcttaatt	ctatactcat	cctctacagg	gagttggcaa	gattcaaaga	caaccaaaga	15540
agtcaacaag	ggatgttcca	cgcttacctc	gtattggtta	gtagcaggca	acgagaactt	15600
atatctagga	tcacccgcaa	attctggggg	cacattcttc	tttactccgg	gaacaaaaag	15660
ttgataaata	agtttatcca	gaatctcaag	tccggctatc	tgatactaga	cttacaccag	15720
aatatcttcg	ttaagaatct	atccaagtca	gagaaacaga	ttattatgac	gggggggttg	15780
aaacgtgagt	gggtttttta	ggtaacagtc	aaggagacca	aagaatggta	taagttagtc	15840
ggatacagtg	ccctgattaa	ggactaattg	gttgaactcc	ggaaccctaa	tcctgcccta	15900
ggtggttagg	cattatttgc	aatatattaa	agaaaacttt	gaaaatacga	agtttctatt	15960
cccagctttg	tctggtggcc	ggcatggtcc	cagcctcctc	gctggcgccg	gctgggcaac	16020
attccgaggg	gaccgtcccc	tcggtaatgg	cgaatgggac	gcggccgatc	cggctgctaa	16080
caaagccccg	aaggaagctg	agttggctgc	tgccaccgct	gagcaataac	tagcataacc	16140

B09995A - SQL - eolf-seq1

ccttggggcc	tctaaacggg	tcttgagggg	ttttttgctg	aaaggaggaa	ctatatccgg	16200
atgcggccgc	gggccctatg	gtaccagct	ttgttcct	ttagtgaggg	ttaattccga	16260
gcttggcgta	atcatggtca	tagctgtttc	ctgtgtgaaa	ttgttatccg	ctcacaattc	16320
cacacaacat	aggagccgga	agcataaagt	gtaaagcctg	gggtgcctaa	tgagtgaggt	16380
aactcacatt	aattgcgttg	cgctcactgc	ccgctttcca	gtcgggaaac	ctgtcgtgcc	16440
agctgcatta	atgaatcggc	caacgcgcgg	ggagaggcgg	tttgcgtatt	gggcgctctt	16500
ccgcttcctc	gctcactgac	tcgctgcgct	cggtcgttcg	gctgcggcga	gcggtatcag	16560
ctcactcaaa	ggcggtaata	cggttatcca	cagaatcagg	ggataacgca	ggaaagaaca	16620
tgtgagcaaa	aggccagcaa	aaggccagga	accgtaaaaa	ggccgcgttg	ctggcgtttt	16680
tccataggct	cggccccct	gacgagcatc	acaaaaatcg	acgctcaagt	cagaggtggc	16740
gaaacccgac	aggactataa	agataccagg	cgttcccccc	tggaagctcc	ctcgtgcgct	16800
ctcctgttcc	gaccctgccg	cttaccggat	acctgtccgc	ctttctccct	tcgggaagcg	16860
tggcgctttc	tcaatgctca	cgctgtaggt	atctcagttc	ggtgtaggtc	gttcgctcca	16920
agctgggctg	tgtgcacgaa	cccccgttc	agcccgaccg	ctgcgcctta	tccggttaact	16980
atcgtcttga	gtccaacccg	gtaagacacg	acttatcgcc	actggcagca	gccactggta	17040
acaggattag	cagagcgagg	tatgtaggcg	gtgctacaga	gttcttgaag	tggtggccta	17100
actacggcta	cactagaagg	acagtatttg	gtatctgcgc	tctgctgaag	ccagttacct	17160
tcggaaaaag	agttggtagc	tcttgatccg	gcaaacaac	caccgctggg	agcggtggtt	17220
tttttgtttg	caagcagcag	attacgcgca	gaaaaaaagg	atctcaagaa	gaccccttga	17280
tcttttctac	ggggtctgac	gctcagtggg	acgaaaactc	acgttaaggg	attttggtca	17340
tgagattatc	aaaaaggatc	ttcacctaga	tccttttaaa	ttaaaaatga	agttttaaat	17400
caatctaaag	tatatatgag	taaacttggg	ctgacagtta	ccaatgctta	atcagtgagg	17460
cacctatctc	agcgatctgt	ctatttcggt	catccatagt	tgccctgactg	cccgtcgtgt	17520
agataactac	gatacgggag	ggcttaccat	ctggccccag	tgctgcaatg	ataccgcgag	17580
accacgctc	accgggtcca	gatttatcag	caataaacca	gccagccgga	agggccgagc	17640
gcagaagtgg	tcctgcaact	ttatccgcct	ccatccagtc	tattaattgt	tgccgggaag	17700
ctagagtaag	tagttcgcca	gttaatagtt	tgcgcaacgt	tgttgccatt	gctacaggca	17760
tcgtgggtgc	acgctcgtcg	tttggtatgg	cttcattcag	ctccggttcc	caacgatcaa	17820
ggcgagttac	atgatcccc	atgttggtgaa	aaaaagcggg	tagctccttc	ggtcctccga	17880
tcgttgctcag	aagtaagttg	gccgcagtgt	tatcactcat	gcttatggca	gcactgcata	17940
attctcttac	tgtcatgcc	tccgtaagat	gcttttctgt	gactggtgag	tactcaacca	18000

B09995A - SQL - eolf-seq1

```

agtcattctg agaatagtgt atgcggcgac cgagttgctc ttgcccggcg tcaatacggg 18060
ataataccgc gccacatagc agaactttaa aagtgtcat cattggaaaa cgttcttcgg 18120
ggcgaaaaact ctcaaggatc ttaccgctgt tgagatccag ttcgatgtaa cccactcgtg 18180
cacccaactg atcttcagca tcttttactt tcaccagcgt ttctgggtga gcaaaaacag 18240
gaaggcaaaa tgccgcaaaa aagggaataa gggcgacacg gaaatgttga atactcatac 18300
tcttcctttt tcaatattat tgaagcattt atcaggggta ttgtctcatg agcggataca 18360
tatttgaatg tatttagaaa aataaaciaa taggggttcc gcgcacattt ccccgaaaag 18420
tgccacctga aattgtaaac gttaatat tttgtaaaatt cgcgttaa ttttgttaaa 18480
tcagctcatt ttttaacca taggccgaaa tcggcaaaat cctttataaa tcaaaagaat 18540
agaccgagat aggggttgagt gttgttccag tttggaacia gagtccacta ttaaagaacg 18600
tggaactcaa cgtcaaagg cgaaaaaccg tctatcagg cgatggccca ctacgtgaac 18660
catcaccta atcaagtttt ttggggctga ggtgccgtaa agcactaaat cggaacccta 18720
aaggagagccc ccgatttaga gcttgacggg gaaagccggc gaacgtggcg agaaaggaag 18780
ggaagaaagc gaaaggagcg ggcgctaggg cgctggcaag tgtagcggtc acgctgcgcg 18840
taaccaccac acccgccgcg cttaatgcgc cgctacagg cgcgctccat tcgccattca 18900
ggctgcgcaa ctgttgggaa gggcgatcgg tgcgggcctc ttcgctatta cgccagccac 18960
cgcggtg 18967

```

<210> 2
 <211> 1797
 <212> DNA
 <213> Chikungunya virus

<220>
 <221> misc_feature
 <223> soluble glycoprotein E2 strain 05.115

<220>
 <221> CDS
 <222> (1)..(1797)

<400> 2
 ata ccc gtg cac atg aag tcc gac gct tcg aag ttc acc cat gag aaa 48
 Ile Pro Val His Met Lys Ser Asp Ala Ser Lys Phe Thr His Glu Lys
 1 5 10 15
 ccg gag ggg tac tac aac tgg cac cac gga gca gta cag tac tca gga 96
 Pro Glu Gly Tyr Tyr Asn Trp His His Gly Ala Val Gln Tyr Ser Gly
 20 25 30
 ggc cgg ttc acc atc cct aca ggt gct ggc aaa cca ggg gac agc ggc 144
 Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly Lys Pro Gly Asp Ser Gly
 35 40 45
 aga ccg atc ttc gac aac aag gga cgc gtg gtg gcc ata gtc tta gga 192
 Page 11

B09995A - SQL - eolf-seql

Arg	Pro	Ile	Phe	Asp	Asn	Lys	Gly	Arg	Val	Val	Ala	Ile	Val	Leu	Gly		
50						55					60						
gga	gct	aat	gaa	gga	gcc	cgt	aca	gcc	ctc	tcg	gtg	gtg	acc	tgg	aat	240	
Gly	Ala	Asn	Glu	Gly	Ala	Arg	Thr	Ala	Leu	Ser	Val	Val	Thr	Trp	Asn	80	
65					70				75								
aaa	gac	att	gtc	act	aaa	atc	acc	ccc	gag	ggg	gcc	gaa	gag	tgg	agt	288	
Lys	Asp	Ile	Val	Thr	Lys	Ile	Thr	Pro	Glu	Gly	Ala	Glu	Glu	Trp	Ser	95	
			85						90								
ctt	gcc	atc	cca	gtt	atg	tgc	ctg	ttg	gca	aac	acc	acg	ttc	ccc	tgc	336	
Leu	Ala	Ile	Pro	Val	Met	Cys	Leu	Leu	Ala	Asn	Thr	Thr	Phe	Pro	Cys	110	
			100				105										
tcc	cag	ccc	cct	tgc	acg	ccc	tgc	tgc	tac	gaa	aag	gaa	ccg	gag	gaa	384	
Ser	Gln	Pro	Pro	Cys	Thr	Pro	Cys	Cys	Tyr	Glu	Lys	Glu	Pro	Glu	Glu	125	
		115					120										
acc	cta	cgc	atg	ctt	gag	gac	aac	gtc	atg	aga	cct	ggg	tac	tat	cag	432	
Thr	Leu	Arg	Met	Leu	Glu	Asp	Asn	Val	Met	Arg	Pro	Gly	Tyr	Tyr	Gln	140	
	130					135											
ctg	cta	caa	gca	tcc	tta	aca	tgt	tct	ccc	cac	cgc	cag	cga	cgc	agc	480	
Leu	Leu	Gln	Ala	Ser	Leu	Thr	Cys	Ser	Pro	His	Arg	Gln	Arg	Arg	Ser	160	
					150					155							
acc	aag	gac	aac	ttc	aat	gtc	tat	aaa	gcc	aca	aga	cca	tac	tta	gct	528	
Thr	Lys	Asp	Asn	Phe	Asn	Val	Tyr	Lys	Ala	Thr	Arg	Pro	Tyr	Leu	Ala	170	
				165					170					175			
cac	tgt	ccc	gac	tgt	gga	gaa	ggg	cac	tcg	tgc	cat	agt	ccc	gta	gca	576	
His	Cys	Pro	Asp	Cys	Gly	Glu	Gly	His	Ser	Cys	His	Ser	Pro	Val	Ala	180	
			180					185					190				
cta	gaa	cgc	atc	aga	aat	gaa	gcg	aca	gac	ggg	acg	ctg	aaa	atc	cag	624	
Leu	Glu	Arg	Ile	Arg	Asn	Glu	Ala	Thr	Asp	Gly	Thr	Leu	Lys	Ile	Gln	200	
		195					200					205					
gtc	tcc	ttg	caa	atc	gga	ata	aag	acg	gat	gac	agc	cac	gat	tgg	acc	672	
Val	Ser	Leu	Gln	Ile	Gly	Ile	Lys	Thr	Asp	Asp	Ser	His	Asp	Trp	Thr	210	
		210				215					220						
aag	ctg	cgt	tat	atg	gac	aac	cac	atg	cca	gca	gac	gca	gag	agg	gcg	720	
Lys	Leu	Arg	Tyr	Met	Asp	Asn	His	Met	Pro	Ala	Asp	Ala	Glu	Arg	Ala	225	
					230					235					240		
ggg	cta	ttt	gta	aga	aca	tca	gca	ccg	tgt	acg	att	act	gga	aca	atg	768	
Gly	Leu	Phe	Val	Arg	Thr	Ser	Ala	Pro	Cys	Thr	Ile	Thr	Gly	Thr	Met	245	
				245					250					255			
gga	cac	ttc	atc	ctg	gcc	cga	tgt	cca	aaa	ggg	gaa	act	ctg	acg	gtg	816	
Gly	His	Phe	Ile	Leu	Ala	Arg	Cys	Pro	Lys	Gly	Glu	Thr	Leu	Thr	Val	260	
			260				265						270				
gga	ttc	act	gac	agt	agg	aag	att	agt	cac	tca	tgt	acg	cac	cca	ttt	864	
Gly	Phe	Thr	Asp	Ser	Arg	Lys	Ile	Ser	His	Ser	Cys	Thr	His	Pro	Phe	275	
		275					280					285					
cac	cac	gac	cct	cct	gtg	ata	ggt	cgg	gaa	aaa	ttc	cat	tcc	cga	ccg	912	
His	His	Asp	Pro	Pro	Val	Ile	Gly	Arg	Glu	Lys	Phe	His	Ser	Arg	Pro	290	
						295					300						

B09995A - SQL - eolf-seq1																
cag	cac	ggt	aaa	gag	ata	cct	tgc	agc	acg	tac	gtg	cag	agc	acc	gcc	
Gln	His	Gly	Lys	Glu	Ile	Pro	Cys	Ser	Thr	Tyr	Val	Gln	Ser	Thr	Ala	960
305					310					315					320	
gca	act	acc	gag	gag	ata	gag	gta	cac	atg	ccc	cca	gac	acc	cct	gat	1008
Ala	Thr	Thr	Glu	Glu	Ile	Glu	Val	His	Met	Pro	Pro	Asp	Thr	Pro	Asp	
				325					330					335		
cgc	aca	tta	atg	tca	caa	cag	tcc	ggc	aac	gta	aag	atc	aca	gtc	aat	1056
Arg	Thr	Leu	Met	Ser	Gln	Gln	Ser	Gly	Asn	Val	Lys	Ile	Thr	Val	Asn	
			340					345					350			
ggc	cag	acg	gtg	cgg	tac	aag	tgt	aat	tgc	ggg	ggc	tca	aat	gaa	gga	1104
Gly	Gln	Thr	Val	Arg	Tyr	Lys	Cys	Asn	Cys	Gly	Gly	Ser	Asn	Glu	Gly	
		355					360					365				
cta	aca	act	aca	gac	aaa	gtg	att	aat	aac	tgc	aag	gtt	gat	caa	tgt	1152
Leu	Thr	Thr	Thr	Asp	Lys	Val	Ile	Asn	Asn	Cys	Lys	Val	Asp	Gln	Cys	
	370					375					380					
cat	gcc	gcg	gtc	acc	aat	cac	aaa	aag	tgg	cag	tat	aac	tcc	cct	ctg	1200
His	Ala	Ala	Val	Thr	Asn	His	Lys	Lys	Trp	Gln	Tyr	Asn	Ser	Pro	Leu	
385					390					395					400	
gtc	ccg	cgt	aat	gct	gaa	ctt	ggg	gac	cga	aaa	gga	aaa	att	cac	atc	1248
Val	Pro	Arg	Asn	Ala	Glu	Leu	Gly	Asp	Arg	Lys	Gly	Lys	Ile	His	Ile	
				405				410						415		
ccg	ttt	ccg	ctg	gca	aat	gta	aca	tgc	agg	gtg	cct	aaa	gca	agg	aac	1296
Pro	Phe	Pro	Leu	Ala	Asn	Val	Thr	Cys	Arg	Val	Pro	Lys	Ala	Arg	Asn	
			420					425					430			
ccc	acc	gtg	acg	tac	ggg	aaa	aac	caa	gtc	atc	atg	cta	ctg	tat	cct	1344
Pro	Thr	Val	Thr	Tyr	Gly	Lys	Asn	Gln	Val	Ile	Met	Leu	Leu	Tyr	Pro	
		435					440					445				
gac	cac	cca	aca	ctc	ctg	tcc	tac	cgg	aat	atg	gga	gaa	gaa	cca	aac	1392
Asp	His	Pro	Thr	Leu	Leu	Ser	Tyr	Arg	Asn	Met	Gly	Glu	Glu	Pro	Asn	
	450					455					460					
tat	caa	gaa	gag	tgg	gtg	atg	cat	aag	aag	gaa	gtc	gtg	cta	acc	gtg	1440
Tyr	Gln	Glu	Glu	Trp	Val	Met	His	Lys	Lys	Glu	Val	Val	Leu	Thr	Val	
465					470					475					480	
ccg	act	gaa	ggg	ctc	gag	gtc	acg	tgg	ggc	aac	aac	gag	ccg	tat	aag	1488
Pro	Thr	Glu	Gly	Leu	Glu	Val	Thr	Trp	Gly	Asn	Asn	Glu	Pro	Tyr	Lys	
				485					490					495		
tat	tgg	ccg	cag	tta	tct	aca	aac	ggg	aca	gcc	cat	ggc	cac	ccg	cat	1536
Tyr	Trp	Pro	Gln	Leu	Ser	Thr	Asn	Gly	Thr	Ala	His	Gly	His	Pro	His	
			500					505					510			
gag	ata	att	ctg	tat	tat	tat	gag	ctg	tac	ccc	act	atg	act	gta	gta	1584
Glu	Ile	Ile	Leu	Tyr	Tyr	Tyr	Glu	Leu	Tyr	Pro	Thr	Met	Thr	Val	Val	
		515					520					525				
gtt	gtg	tca	gtg	gcc	acg	ttc	ata	ctc	ctg	tcg	atg	gtg	ggg	atg	gca	1632
Val	Val	Ser	Val	Ala	Thr	Phe	Ile	Leu	Leu	Ser	Met	Val	Gly	Met	Ala	
		530				535					540					
gcg	ggg	atg	tgc	atg	tgt	gca	cga	cgc	aga	tgc	atc	aca	ccg	tat	gaa	1680
Ala	Gly	Met	Cys	Met	Cys	Ala	Arg	Arg	Arg	Cys	Ile	Thr	Pro	Tyr	Glu	
545					550					555					560	

B09995A - SQL - eolf-seq1

ctg aca cca gga gct acc gtc cct ttc ctg ctt agc cta ata tgc tgc 1728
 Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu Ser Leu Ile Cys Cys
 565 570 575

atc aga aca gct aaa gcg gcc aca tac caa gag gct gcg ata tac ctg 1776
 Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln Glu Ala Ala Ile Tyr Leu
 580 585 590

tgg aac gag cag caa cct tta 1797
 Trp Asn Glu Gln Gln Pro Leu
 595

<210> 3
 <211> 599
 <212> PRT
 <213> Chikungunya virus

<400> 3

Ile Pro Val His Met Lys Ser Asp Ala Ser Lys Phe Thr His Glu Lys
 1 5 10 15

Pro Glu Gly Tyr Tyr Asn Trp His His Gly Ala Val Gln Tyr Ser Gly
 20 25 30

Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly Lys Pro Gly Asp Ser Gly
 35 40 45

Arg Pro Ile Phe Asp Asn Lys Gly Arg Val Val Ala Ile Val Leu Gly
 50 55 60

Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu Ser Val Val Thr Trp Asn
 65 70 75 80

Lys Asp Ile Val Thr Lys Ile Thr Pro Glu Gly Ala Glu Glu Trp Ser
 85 90 95

Leu Ala Ile Pro Val Met Cys Leu Leu Ala Asn Thr Thr Phe Pro Cys
 100 105 110

Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr Glu Lys Glu Pro Glu Glu
 115 120 125

Thr Leu Arg Met Leu Glu Asp Asn Val Met Arg Pro Gly Tyr Tyr Gln
 130 135 140

Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro His Arg Gln Arg Arg Ser
 145 150 155 160

Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu Ala
 165 170 175

B09995A - SQL - eolf-seql

06/27/2018 10:03 00421

His Cys Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Val Ala
180 185 190

Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile Gln
195 200 205

Val Ser Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp Thr
210 215 220

Lys Leu Arg Tyr Met Asp Asn His Met Pro Ala Asp Ala Glu Arg Ala
225 230 235 240

Gly Leu Phe Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr Met
245 250 255

Gly His Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr Val
260 265 270

Gly Phe Thr Asp Ser Arg Lys Ile Ser His Ser Cys Thr His Pro Phe
275 280 285

His His Asp Pro Pro Val Ile Gly Arg Glu Lys Phe His Ser Arg Pro
290 295 300

Gln His Gly Lys Glu Ile Pro Cys Ser Thr Tyr Val Gln Ser Thr Ala
305 310 315 320

Ala Thr Thr Glu Glu Ile Glu Val His Met Pro Pro Asp Thr Pro Asp
325 330 335

Arg Thr Leu Met Ser Gln Gln Ser Gly Asn Val Lys Ile Thr Val Asn
340 345 350

Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys Gly Gly Ser Asn Glu Gly
355 360 365

Leu Thr Thr Thr Asp Lys Val Ile Asn Asn Cys Lys Val Asp Gln Cys
370 375 380

His Ala Ala Val Thr Asn His Lys Lys Trp Gln Tyr Asn Ser Pro Leu
385 390 395 400

Val Pro Arg Asn Ala Glu Leu Gly Asp Arg Lys Gly Lys Ile His Ile
405 410 415

Pro Phe Pro Leu Ala Asn Val Thr Cys Arg Val Pro Lys Ala Arg Asn
Page 15

B09995A - SQL - eof-seq1
425 430

420

Pro Thr Val Thr Tyr Gly Lys Asn Gln Val Ile Met Leu Leu Tyr Pro
435 440 445Asp His Pro Thr Leu Leu Ser Tyr Arg Asn Met Gly Glu Glu Pro Asn
450 455 460Tyr Gln Glu Glu Trp Val Met His Lys Lys Glu Val Val Leu Thr Val
465 470 475 480Pro Thr Glu Gly Leu Glu Val Thr Trp Gly Asn Asn Glu Pro Tyr Lys
485 490 495Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr Ala His Gly His Pro His
500 505 510Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro Thr Met Thr Val Val
515 520 525Val Val Ser Val Ala Thr Phe Ile Leu Leu Ser Met Val Gly Met Ala
530 535 540Ala Gly Met Cys Met Cys Ala Arg Arg Arg Cys Ile Thr Pro Tyr Glu
545 550 555 560Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu Ser Leu Ile Cys Cys
565 570 575Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln Glu Ala Ala Ile Tyr Leu
580 585 590Trp Asn Glu Gln Gln Pro Leu
595

<210> 4
 <211> 1797
 <212> DNA
 <213> Chikungunya virus

<220>
 <221> misc_feature
 <223> soluble glycoprotein E2 strain 06.21

<220>
 <221> CDS
 <222> (1)..(1797)

<400> 4
 ata ccc gtg cac atg aag tcc gac gct tcg aag ttc acc cat gag aaa
 Page 16

In a particular embodiment of the invention, the polynucleotide encoding the at least one protein of the CHIKV, or each of these polynucleotides, is cloned into an ATU (Additional Transcription Unit) inserted in the cDNA of the measles virus. ATU sequences are known from the skilled person and comprise, for use in steps of cloning into cDNA of MV, cis-acting sequences necessary for MV-dependant expression of a transgene, such as a promoter of the gene preceding, in MV cDNA, the insert represented by the polynucleotide encoding the CHIKV protein(s) inserted into a multiple cloning sites cassette.

When used to carry out the invention, the ATU is advantageously located in the N-terminal sequence of the cDNA molecule encoding the full-length (+)RNA strand of the antigenome of the MV and is especially located between the P and M genes of this virus or between the H and L genes. It has been observed that the transcription of the viral RNA of MV follows a gradient from the 5' to the 3' end. This explains that, when inserted in the 5' end of the coding sequence of the cDNA, the ATU will enable a more efficient expression of the heterologous DNA sequence (e.g. the polynucleotide encoding the at least one structural protein of the CHIKV) that it contains.

The polynucleotide encoding at least one structural protein of CHIKV may thus be inserted in any intergenic region of the cDNA molecule of the measles virus in particular in an ATU. Particular constructs of the invention are those illustrated in the examples.

In a particular embodiment, when several distinct polynucleotides are present in the DNA construct, each of these polynucleotides encoding at least one structural protein of the CHIKV may be inserted in different sites of MV cDNA, possibly in distinct ATU of the cDNA of the measles virus.

In a preferred embodiment of the invention, the polynucleotide encoding at least one of the structural proteins of CHIKV is inserted in the intergenic region of the P and M genes of the measles virus cDNA molecule, in particular in an ATU.

B09995A - SQL - eolf-seql																
Ile 1	Pro	Val	His	Met 5	Lys	Ser	Asp	Ala 10	Ser 10	Lys	Phe	Thr	His	Glu 15	Lys	
ccg Pro	gag Glu	ggg Gly	tac Tyr 20	tac Tyr	aac Asn	tgg Trp	cac His 25	cac His 25	gga Gly	gca Ala	gta Val	cag Gln 30	tac Tyr 30	tca Ser	gga Gly	96
ggc Gly	cgg Arg	ttc Phe 35	acc Thr	atc Ile	cct Pro	aca Thr	ggt Gly 40	gct Ala	ggc Gly	aaa Lys	cca Pro	ggg Gly 45	gac Asp	agc Ser	ggc Gly	144
aga Arg	ccg Pro 50	atc Ile	ttc Phe	gac Asp	aac Asn 55	aag Lys 55	gga Gly	cgc Arg	gtg Val	gtg Val	gcc Ala 60	ata Ile	gtc Val	tta Leu	gga Gly	192
gga Gly 65	gct Ala	aat Asn	gaa Glu	gga Gly 70	gcc Ala 70	cgt Arg	aca Thr	gcc Ala	ctc Leu 75	tcg Ser 75	gtg Val	gtg Val	acc Thr	tgg Trp	aat Asn 80	240
aaa Lys	gac Asp	att Ile	gtc Val	act Thr 85	aaa Lys	atc Ile	acc Thr	ccc Pro	gag Glu 90	ggg Gly	gcc Ala	gaa Glu	gag Glu	tgg Trp 95	agt Ser	288
ctt Leu	gcc Ala	atc Ile	cca Pro 100	gtt Val	atg Met	tgc Cys	ctg Leu 105	ttg Leu 105	gca Ala	aac Asn	acc Thr	acg Thr	ttc Phe 110	ccc Pro	tgc Cys	336
tcc Ser	cag Gln 115	ccc Pro	cct Pro	tgc Cys	acg Thr	ccc Pro	tgc Cys 120	tgc Cys	tac Tyr	gaa Glu	aag Lys	gaa Glu 125	ccg Pro	gag Glu	gaa Glu	384
acc Thr 130	cta Leu	cgc Arg	atg Met	ctt Leu	gag Glu	gac Asp 135	aac Asn	gtc Val	atg Met	aga Arg	cct Pro 140	ggg Gly	tac Tyr	tat Tyr	cag Gln	432
ctg Leu 145	cta Leu	caa Gln	gca Ala	tcc Ser 150	tta Leu 150	aca Thr	tgt Cys	tct Ser	ccc Pro	cac His 155	cgc Arg	cag Gln	cga Arg	cgc Arg	agc Ser 160	480
acc Thr	aag Lys	gac Asp	aac Asn	ttc Phe 165	aat Asn	gtc Val	tat Tyr	aaa Lys 170	gcc Ala 170	aca Thr	aga Arg	cca Pro	tac Tyr	tta Leu 175	gct Ala	528
cac His	tgt Cys	ccc Pro	gac Asp 180	tgt Cys	gga Gly	gaa Glu	ggg Gly 185	cac His 185	tcg Ser	tgc Cys	cat His	agt Ser 190	ccc Pro	gta Val	gca Ala	576
cta Leu	gaa Glu	cgc Arg 195	atc Ile	aga Arg	aat Asn	gaa Glu	gcg Ala 200	aca Thr	gac Asp	ggg Gly	acg Thr	ctg Leu 205	aaa Lys	atc Ile	cag Gln	624
gtc Val 210	tcc Ser	ttg Leu	caa Gln	atc Ile	gga Gly	ata Ile 215	aag Lys	acg Thr	gat Asp	gac Asp	agc Ser 220	cac His	gat Asp	tgg Trp	acc Thr	672
aag Lys 225	ctg Leu	cgt Arg	tat Tyr	atg Met	gac Asp 230	aac Asn	cac His	atg Met	cca Pro	gca Ala 235	gac Asp	gca Ala	gag Glu	agg Arg	gcg Ala 240	720
ggg Gly	cta Leu	ttt Phe	gta Val	aga Arg 245	aca Thr	tca Ser	gca Ala	ccg Pro	tgt Cys 250	acg Thr	att Ile	act Thr	gga Gly	aca Thr 255	atg Met	768

B09995A - SQL - eolf-seql																	
gga	cac	ttc	atc	ctg	gcc	cga	tgt	cca	aaa	ggg	gaa	act	ctg	acg	gtg		816
Gly	His	Phe	Ile	Leu	Ala	Arg	Cys	Pro	Lys	Gly	Glu	Thr	Leu	Thr	Val		
			260					265					270				
gga	ttc	act	gac	agt	agg	aag	att	agt	cac	tca	tgt	acg	cac	cca	ttt		864
Gly	Phe	Thr	Asp	Ser	Arg	Lys	Ile	Ser	His	Ser	Cys	Thr	His	Pro	Phe		
		275					280					285					
cac	cac	gac	cct	cct	gtg	ata	ggg	cgg	gaa	aaa	ttc	cat	tcc	cga	ccg		912
His	His	Asp	Pro	Pro	Val	Ile	Gly	Arg	Glu	Lys	Phe	His	Ser	Arg	Pro		
		290				295					300						
cag	cac	ggg	aaa	gag	cta	cct	tgc	agc	acg	tac	gtg	cag	agc	acc	gcc		960
Gln	His	Gly	Lys	Glu	Leu	Pro	Cys	Ser	Thr	Tyr	Val	Gln	Ser	Thr	Ala		
305					310					315					320		
gca	act	acc	gag	gag	ata	gag	gta	cac	atg	ccc	cca	gac	acc	cct	gat		1008
Ala	Thr	Thr	Glu	Glu	Ile	Glu	Val	His	Met	Pro	Pro	Asp	Thr	Pro	Asp		
				325					330					335			
cgc	aca	tta	atg	tca	caa	cag	tcc	ggc	aac	gta	aag	atc	aca	gtc	aat		1056
Arg	Thr	Leu	Met	Ser	Gln	Gln	Ser	Gly	Asn	Val	Lys	Ile	Thr	Val	Asn		
			340					345					350				
ggc	cag	acg	gtg	cgg	tac	aag	tgt	aat	tgc	ggg	ggc	tca	aat	gaa	gga		1104
Gly	Gln	Thr	Val	Arg	Tyr	Lys	Cys	Asn	Cys	Gly	Gly	Ser	Asn	Glu	Gly		
		355					360					365					
cta	aca	act	aca	gac	aaa	gtg	att	aat	aac	tgc	aag	gtt	gat	caa	tgt		1152
Leu	Thr	Thr	Thr	Asp	Lys	Val	Ile	Asn	Asn	Cys	Lys	Val	Asp	Gln	Cys		
		370				375					380						
cat	gcc	gcg	gtc	acc	aat	cac	aaa	aag	tgg	cag	tat	aac	tcc	cct	ctg		1200
His	Ala	Ala	Val	Thr	Asn	His	Lys	Lys	Trp	Gln	Tyr	Asn	Ser	Pro	Leu		
385					390					395					400		
gtc	ccg	cgt	aat	gct	gaa	ctt	ggg	gac	cga	aaa	gga	aaa	att	cac	atc		1248
Val	Pro	Arg	Asn	Ala	Glu	Leu	Gly	Asp	Arg	Lys	Gly	Lys	Ile	His	Ile		
				405					410					415			
ccg	ttt	ccg	ctg	gca	aat	gta	aca	tgc	agg	gtg	cct	aaa	gca	agg	aac		1296
Pro	Phe	Pro	Leu	Ala	Asn	Val	Thr	Cys	Arg	Val	Pro	Lys	Ala	Arg	Asn		
			420					425					430				
ccc	acc	gtg	acg	tac	ggg	aaa	aac	caa	gtc	atc	atg	cta	ctg	tat	cct		1344
Pro	Thr	Val	Thr	Tyr	Gly	Lys	Asn	Gln	Val	Ile	Met	Leu	Leu	Tyr	Pro		
		435					440					445					
gac	cac	cca	aca	ctc	ctg	tcc	tac	cgg	aat	atg	gga	gaa	gaa	cca	aac		1392
Asp	His	Pro	Thr	Leu	Leu	Ser	Tyr	Arg	Asn	Met	Gly	Glu	Glu	Pro	Asn		
		450				455					460						
tat	caa	gaa	gag	tgg	gtg	atg	cat	aag	aag	gaa	gtc	gtg	cta	acc	gtg		1440
Tyr	Gln	Glu	Glu	Trp	Val	Met	His	Lys	Lys	Glu	Val	Val	Leu	Thr	Val		
465					470					475					480		
ccg	act	gaa	ggg	ctc	gag	gtc	acg	tgg	ggc	aac	aac	gag	ccg	tat	aag		1488
Pro	Thr	Glu	Gly	Leu	Glu	Val	Thr	Trp	Gly	Asn	Asn	Glu	Pro	Tyr	Lys		
				485					490					495			
tat	tgg	ccg	cag	tta	tct	aca	aac	ggg	aca	gcc	cat	ggc	cac	ccg	cat		1536
Tyr	Trp	Pro	Gln	Leu	Ser	Thr	Asn	Gly	Thr	Ala	His	Gly	His	Pro	His		
			500					505					510				

B09995A - SQL - eolf-seql

gag ata att ctg tat tat tat gag ctg tac ccc act atg act gta gta 1584
 Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro Thr Met Thr Val Val
 515 520 525
 gtt gtg tca gtg gcc acg ttc ata ctc ctg tcg atg gtg ggt atg gca 1632
 Val Val Ser Val Ala Thr Phe Ile Leu Leu Ser Met Val Gly Met Ala
 530 535 540
 gcg ggg atg tgc atg cgt gca cga cgc aga tgc atc aca ccg tat gaa 1680
 Ala Gly Met Cys Met Arg Ala Arg Arg Arg Cys Ile Thr Pro Tyr Glu
 545 550 555 560
 ctg aca cca gga gct acc gtc cct ttc ctg ctt agc cta ata tgc tgc 1728
 Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu Ser Leu Ile Cys Cys
 565 570 575
 atc aga aca gct aaa gcg gcc aca tac caa gag gct gcg ata tac ctg 1776
 Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln Glu Ala Ala Ile Tyr Leu
 580 585 590
 tgg aac gag cag caa cct tta 1797
 Trp Asn Glu Gln Gln Pro Leu
 595

<210> 5
 <211> 599
 <212> PRT
 <213> Chikungunya virus

<400> 5

Ile Pro Val His Met Lys Ser Asp Ala Ser Lys Phe Thr His Glu Lys
 1 5 10 15
 Pro Glu Gly Tyr Tyr Asn Trp His His Gly Ala Val Gln Tyr Ser Gly
 20 25 30
 Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly Lys Pro Gly Asp Ser Gly
 35 40 45
 Arg Pro Ile Phe Asp Asn Lys Gly Arg Val Val Ala Ile Val Leu Gly
 50 55 60
 Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu Ser Val Val Thr Trp Asn
 65 70 75 80
 Lys Asp Ile Val Thr Lys Ile Thr Pro Glu Gly Ala Glu Glu Trp Ser
 85 90 95
 Leu Ala Ile Pro Val Met Cys Leu Leu Ala Asn Thr Thr Phe Pro Cys
 100 105 110
 Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr Glu Lys Glu Pro Glu Glu
 115 120 125

B09995A - SQL - eolf-seql

Thr Leu Arg Met Leu Glu Asp Asn Val Met Arg Pro Gly Tyr Tyr Gln
130 135 140

Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro His Arg Gln Arg Arg Ser
145 150 155 160

Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu Ala
165 170 175

His Cys Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Val Ala
180 185 190

Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile Gln
195 200 205

Val Ser Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp Thr
210 215 220

Lys Leu Arg Tyr Met Asp Asn His Met Pro Ala Asp Ala Glu Arg Ala
225 230 235 240

Gly Leu Phe Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr Met
245 250 255

Gly His Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr Val
260 265 270

Gly Phe Thr Asp Ser Arg Lys Ile Ser His Ser Cys Thr His Pro Phe
275 280 285

His His Asp Pro Pro Val Ile Gly Arg Glu Lys Phe His Ser Arg Pro
290 295 300

Gln His Gly Lys Glu Leu Pro Cys Ser Thr Tyr Val Gln Ser Thr Ala
305 310 315 320

Ala Thr Thr Glu Glu Ile Glu Val His Met Pro Pro Asp Thr Pro Asp
325 330 335

Arg Thr Leu Met Ser Gln Gln Ser Gly Asn Val Lys Ile Thr Val Asn
340 345 350

Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys Gly Gly Ser Asn Glu Gly
355 360 365

Leu Thr Thr Thr Asp Lys Val Ile Asn Asn Cys Lys Val Asp Gln Cys
Page 20

06/27/2018 10:03 00426

B09995A - SQL - eolf-seql

370

375

380

His Ala Ala Val Thr Asn His Lys Lys Trp Gln Tyr Asn Ser Pro Leu
 385 390 395 400

Val Pro Arg Asn Ala Glu Leu Gly Asp Arg Lys Gly Lys Ile His Ile
 405 410 415

Pro Phe Pro Leu Ala Asn Val Thr Cys Arg Val Pro Lys Ala Arg Asn
 420 425 430

Pro Thr Val Thr Tyr Gly Lys Asn Gln Val Ile Met Leu Leu Tyr Pro
 435 440 445

Asp His Pro Thr Leu Leu Ser Tyr Arg Asn Met Gly Glu Glu Pro Asn
 450 455 460

Tyr Gln Glu Glu Trp Val Met His Lys Lys Glu Val Val Leu Thr Val
 465 470 475 480

Pro Thr Glu Gly Leu Glu Val Thr Trp Gly Asn Asn Glu Pro Tyr Lys
 485 490 495

Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr Ala His Gly His Pro His
 500 505 510

Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro Thr Met Thr Val Val
 515 520 525

Val Val Ser Val Ala Thr Phe Ile Leu Leu Ser Met Val Gly Met Ala
 530 535 540

Ala Gly Met Cys Met Arg Ala Arg Arg Arg Cys Ile Thr Pro Tyr Glu
 545 550 555 560

Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu Ser Leu Ile Cys Cys
 565 570 575

Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln Glu Ala Ala Ile Tyr Leu
 580 585 590

Trp Asn Glu Gln Gln Pro Leu
 595

<210> 6

<211> 1797

<212> DNA

<213> Chikungunya virus

<220>
<221> CDS
<222> (1)..(1797)

Page 22

B09995A - SQL - eolf-seql																
gtc	tcc	ttg	caa	atc	gga	ata	aag	acg	gat	gac	agc	cac	gat	tgg	acc	
Val	Ser	Leu	Gln	Ile	Gly	Ile	Lys	Thr	Asp	Asp	Ser	His	Asp	Trp	Thr	672
210						215					220					
aag	ctg	cgt	tat	atg	gac	aac	cac	atg	cca	gca	gac	gca	gag	agg	gcg	720
Lys	Leu	Arg	Tyr	Met	Asp	Asn	His	Met	Pro	Ala	Asp	Ala	Glu	Arg	Ala	
225					230					235					240	
ggg	cta	ttt	gta	aga	aca	tca	gca	ccg	tgt	acg	att	act	gga	aca	atg	768
Gly	Leu	Phe	Val	Arg	Thr	Ser	Ala	Pro	Cys	Thr	Ile	Thr	Gly	Thr	Met	
				245					250					255		
gga	cac	ttc	atc	ctg	gcc	cga	tgt	cca	aaa	ggg	gaa	act	ctg	acg	gtg	816
Gly	His	Phe	Ile	Leu	Ala	Arg	Cys	Pro	Lys	Gly	Glu	Thr	Leu	Thr	Val	
			260					265					270			
gga	ttc	act	gac	agt	agg	aag	att	agt	cac	tca	tgt	acg	cac	cca	ttt	864
Gly	Phe	Thr	Asp	Ser	Arg	Lys	Ile	Ser	His	Ser	Cys	Thr	His	Pro	Phe	
			275				280					285				
cac	cac	gac	cct	cct	gtg	ata	ggg	cgg	gaa	aaa	ttc	cat	tcc	cga	ccg	912
His	His	Asp	Pro	Pro	Val	Ile	Gly	Arg	Glu	Lys	Phe	His	Ser	Arg	Pro	
			290			295					300					
cag	cac	ggg	aaa	gag	cta	cct	tgc	agc	acg	tac	gtg	cag	agc	acc	gcc	960
Gln	His	Gly	Lys	Glu	Leu	Pro	Cys	Ser	Thr	Tyr	Val	Gln	Ser	Thr	Ala	
305					310					315					320	
gca	act	acc	gag	gag	ata	gag	gta	cac	atg	ccc	cca	gac	acc	cct	gat	1008
Ala	Thr	Thr	Glu	Glu	Ile	Glu	Val	His	Met	Pro	Pro	Asp	Thr	Pro	Asp	
				325					330					335		
cgc	aca	tta	atg	tca	caa	cag	tcc	ggc	aac	gta	aag	atc	aca	gtc	aat	1056
Arg	Thr	Leu	Met	Ser	Gln	Gln	Ser	Gly	Asn	Val	Lys	Ile	Thr	Val	Asn	
			340					345					350			
ggc	cag	acg	gtg	cgg	tac	aag	tgt	aat	tgc	ggg	ggc	tca	aat	gaa	gga	1104
Gly	Gln	Thr	Val	Arg	Tyr	Lys	Cys	Asn	Cys	Gly	Gly	Ser	Asn	Glu	Gly	
			355				360					365				
cta	aca	act	aca	gac	aaa	gtg	att	aat	aac	tgc	aag	gtt	gat	caa	tgt	1152
Leu	Thr	Thr	Thr	Asp	Lys	Val	Ile	Asn	Asn	Cys	Lys	Val	Asp	Gln	Cys	
						375					380					
cat	gcc	gcg	gtc	acc	aat	cac	aaa	aag	tgg	cag	tat	aac	tcc	cct	ctg	1200
His	Ala	Ala	Val	Thr	Asn	His	Lys	Lys	Trp	Gln	Tyr	Asn	Ser	Pro	Leu	
385					390					395					400	
gtc	ccg	cgt	aat	gct	gaa	ctt	ggg	gac	cga	aaa	gga	aaa	att	cac	atc	1248
Val	Pro	Arg	Asn	Ala	Glu	Leu	Gly	Asp	Arg	Lys	Gly	Lys	Ile	His	Ile	
				405					410					415		
ccg	ttt	ccg	ctg	gca	aat	gta	aca	tgc	agg	gtg	cct	aaa	gca	agg	aac	1296
Pro	Phe	Pro	Leu	Ala	Asn	Val	Thr	Cys	Arg	Val	Pro	Lys	Ala	Arg	Asn	
				420				425					430			
ccc	acc	gtg	acg	tac	ggg	aaa	aac	caa	gtc	atc	atg	cta	ctg	tat	cct	1344
Pro	Thr	Val	Thr	Tyr	Gly	Lys	Asn	Gln	Val	Ile	Met	Leu	Leu	Tyr	Pro	
			435				440					445				
gac	cac	cca	aca	ctc	ctg	tcc	tac	cgg	aat	atg	gga	gaa	gaa	cca	aac	1392
Asp	His	Pro	Thr	Leu	Leu	Ser	Tyr	Arg	Asn	Met	Gly	Glu	Glu	Pro	Asn	
			450			455					460					

B09995A - SQL - eolf-seql

tat	caa	gaa	gag	tgg	gtg	atg	cat	aag	aag	gaa	gtc	gtg	cta	acc	gtg	1440
Tyr	Gln	Glu	Glu	Trp	Val	Met	His	Lys	Lys	Glu	Val	Val	Leu	Thr	Val	
465					470					475					480	
ccg	act	gaa	ggg	ctc	gag	gtc	acg	tgg	ggc	aac	aac	gag	ccg	tat	aag	1488
Pro	Thr	Glu	Gly	Leu	Glu	Val	Thr	Trp	Gly	Asn	Asn	Glu	Pro	Tyr	Lys	
				485					490					495		
tat	tgg	ccg	cag	tta	tct	aca	aac	ggg	aca	gcc	cat	ggc	cac	ccg	cat	1536
Tyr	Trp	Pro	Gln	Leu	Ser	Thr	Asn	Gly	Thr	Ala	His	Gly	His	Pro	His	
			500					505					510			
gag	ata	att	ctg	tat	tat	tat	gag	ctg	tac	ccc	act	atg	act	gta	gta	1584
Glu	Ile	Ile	Leu	Tyr	Tyr	Tyr	Glu	Leu	Tyr	Pro	Thr	Met	Thr	Val	Val	
		515					520					525				
gtt	gtg	tca	gtg	gcc	acg	ttc	ata	ctc	ctg	tcg	atg	gtg	ggg	atg	gca	1632
Val	Val	Ser	Val	Ala	Thr	Phe	Ile	Leu	Leu	Ser	Met	Val	Gly	Met	Ala	
	530					535					540					
gcg	ggg	atg	tgc	atg	tgt	gca	cga	cgc	aga	tgc	atc	aca	ccg	tat	gaa	1680
Ala	Gly	Met	Cys	Met	Cys	Ala	Arg	Arg	Arg	Cys	Ile	Thr	Pro	Tyr	Glu	
545					550					555					560	
ctg	aca	cca	gga	gct	acc	gtc	cct	ttc	ctg	ctt	agc	cta	ata	tgc	tgc	1728
Leu	Thr	Pro	Gly	Ala	Thr	Val	Pro	Phe	Leu	Leu	Ser	Leu	Ile	Cys	Cys	
				565					570					575		
atc	aga	aca	gct	aaa	gcg	gcc	aca	tac	caa	gag	gct	gcg	ata	tac	ctg	1776
Ile	Arg	Thr	Ala	Lys	Ala	Ala	Thr	Tyr	Gln	Glu	Ala	Ala	Ile	Tyr	Leu	
			580					585					590			
tgg	aac	gag	cag	caa	cct	tta										1797
Trp	Asn	Glu	Gln	Gln	Pro	Leu										
		595														

<210> 7
 <211> 599
 <212> PRT
 <213> Chikungunya virus

<400> 7

Ile Pro Val His Met Lys Ser Asp Ala Ser Lys Phe Thr His Glu Lys
1 5 10 15

Pro Glu Gly Tyr Tyr Asn Trp His His Gly Ala Val Gln Tyr Ser Gly
20 25 30

Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly Lys Pro Gly Asp Ser Gly
35 40 45

Arg Pro Ile Phe Asp Asn Lys Gly Arg Val Val Ala Ile Val Leu Gly
50 55 60

Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu Ser Val Val Thr Trp Asn
65 70 75 80

B09995A - SQL - eolf-seql

Lys Asp Ile Val Thr Lys Ile Thr Pro Glu Gly Ala Glu Glu Trp Ser
85 90 95

Leu Ala Ile Pro Val Met Cys Leu Leu Ala Asn Thr Thr Phe Pro Cys
100 105 110

Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr Glu Lys Glu Pro Glu Glu
115 120 125

Thr Leu Arg Met Leu Glu Asp Asn Val Met Arg Pro Gly Tyr Tyr Gln
130 135 140

Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro His Arg Gln Arg Arg Ser
145 150 155 160

Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu Ala
165 170 175

His Cys Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Val Ala
180 185 190

Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile Gln
195 200 205

Val Ser Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp Thr
210 215 220

Lys Leu Arg Tyr Met Asp Asn His Met Pro Ala Asp Ala Glu Arg Ala
225 230 235 240

Gly Leu Phe Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr Met
245 250 255

Gly His Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr Val
260 265 270

Gly Phe Thr Asp Ser Arg Lys Ile Ser His Ser Cys Thr His Pro Phe
275 280 285

His His Asp Pro Pro Val Ile Gly Arg Glu Lys Phe His Ser Arg Pro
290 295 300

Gln His Gly Lys Glu Leu Pro Cys Ser Thr Tyr Val Gln Ser Thr Ala
305 310 315 320

Ala Thr Thr Glu Glu Ile Glu Val His Met Pro Pro Asp Thr Pro Asp

B09995A - SQL - eolf-seql

325

330

335

Arg Thr Leu Met Ser Gln Gln Ser Gly Asn Val Lys Ile Thr Val Asn
340 345 350

Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys Gly Gly Ser Asn Glu Gly
355 360 365

Leu Thr Thr Thr Asp Lys Val Ile Asn Asn Cys Lys Val Asp Gln Cys
370 375 380

His Ala Ala Val Thr Asn His Lys Lys Trp Gln Tyr Asn Ser Pro Leu
385 390 395 400

Val Pro Arg Asn Ala Glu Leu Gly Asp Arg Lys Gly Lys Ile His Ile
405 410 415

Pro Phe Pro Leu Ala Asn Val Thr Cys Arg Val Pro Lys Ala Arg Asn
420 425 430

Pro Thr Val Thr Tyr Gly Lys Asn Gln Val Ile Met Leu Leu Tyr Pro
435 440 445

Asp His Pro Thr Leu Leu Ser Tyr Arg Asn Met Gly Glu Glu Pro Asn
450 455 460

Tyr Gln Glu Glu Trp Val Met His Lys Lys Glu Val Val Leu Thr Val
465 470 475 480

Pro Thr Glu Gly Leu Glu Val Thr Trp Gly Asn Asn Glu Pro Tyr Lys
485 490 495

Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr Ala His Gly His Pro His
500 505 510

Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro Thr Met Thr Val Val
515 520 525

Val Val Ser Val Ala Thr Phe Ile Leu Leu Ser Met Val Gly Met Ala
530 535 540

Ala Gly Met Cys Met Cys Ala Arg Arg Arg Cys Ile Thr Pro Tyr Glu
545 550 555 560

Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu Ser Leu Ile Cys Cys
565 570 575

The expression "encoding" used in the present application defines the ability of the nucleic acid molecules to be transcribed and where appropriate translated for product expression into selected cells or cell lines. Accordingly, the nucleic acid construct of the invention may comprise regulatory elements controlling the transcription of the coding sequences, in particular promoters and termination sequences for the transcription and possibly enhancer and other cis-acting elements. These regulatory elements may be heterologous with respect to the CHIKV polynucleotide sequences.

The term "protein" is used interchangeably with the terms "antigen" or "polypeptide" and defines a molecule resulting from a concatenation of amino acid residues. In particular, the proteins disclosed in the application originate from the CHIKV and are structural proteins that may be identical to native proteins or alternatively that may be derived thereof by mutation, including by substitution (in particular by conservative amino acid residues) or by addition of amino acid residues or by secondary modification after translation or by deletion of portions of the native proteins(s) resulting in fragments having a shortened size with respect to the native protein of reference. Fragments are encompassed within the present invention to the extent that they bear epitopes of the native protein suitable for the elicitation of an immune response in a host in particular in a human host, preferably a response that enables the protection against CHIKV infection or against CHIKV associated disease. Epitopes are in particular of the type of B epitopes involved in the elicitation of a humoral immune response through the activation of the production of antibodies in a host to whom the protein has been administered or in whom it is expressed following administration of the infectious replicative particles of the invention. Epitopes may alternatively be of the type of T epitopes involved in elicitation of Cell Mediated Immune response (CMI response). Fragments may have a size representing more than 50% of the amino-acid sequence size of the native protein of CHIKV, preferably at least 90% or 95%. Alternatively, fragments may be short polypeptides with at least 10 amino acid residues, which harbor epitope(s) of the native protein. Fragments in this respect also include polyepitopes as defined herein.

In a particular embodiment of the invention, the cDNA encoding the nucleotide sequence of the full-length, infectious antigenomic (+) RNA strand of MV in nucleic acid construct complies with the rule of six (6) of the measles virus genome.

B09995A - SQL - eolf-seq1

Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln Glu Ala Ala Ile Tyr Leu
 580 585 590

Trp Asn Glu Gln Gln Pro Leu
 595

<210> 8
 <211> 1797
 <212> DNA
 <213> Chikungunya virus

<220>
 <221> misc_feature
 <223> soluble glycoprotein E2 strain 06.49

<220>
 <221> CDS
 <222> (1)..(1797)

<400> 8 ata ccc gtg cac atg aag tcc gac gct tcg aag ttc acc cat gag aaa Ile Pro Val His Met Lys Ser Asp Ala Ser Lys Phe Thr His Glu Lys 1 5 10 15	48
ccg gag ggg tac tac aac tgg cac cac gga gca gta cag tac tca gga Pro Glu Gly Tyr Tyr Asn Trp His His Gly Ala Val Gln Tyr Ser Gly 20 25 30	96
ggc cgg ttc acc atc cct aca ggt gct ggc aaa cca ggg gac agc ggc Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly Lys Pro Gly Asp Ser Gly 35 40 45	144
aga ccg atc ttc gac aac aag gga cgc gtg gtg gcc ata gtc tta gga Arg Pro Ile Phe Asp Asn Lys Gly Arg Val Val Ala Ile Val Leu Gly 50 55 60	192
gga gct aat gaa gga gcc cgt aca gcc ctc tcg gtg gtg acc tgg aat Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu Ser Val Val Thr Trp Asn 65 70 75 80	240
aaa gac att gtc act aaa atc acc ccc gag ggg gcc gaa gag tgg agt Lys Asp Ile Val Thr Lys Ile Thr Pro Glu Gly Ala Glu Glu Trp Ser 85 90	288
ctt gcc atc cca gtt atg tgc ctg ttg gca aac acc acg ttc ccc tgc Leu Ala Ile Pro Val Met Cys Leu Leu Ala Asn Thr Thr Phe Pro Cys 100 105	336
tcc cag ccc cct tgc acg ccc tgc tgc tac gaa aag gaa ccg gag gaa Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr Glu Lys Glu Pro Glu Glu 115 120 125	384
acc cta cgc atg ctt gag gac aac gtc atg aga cct ggg tac tat cag Thr Leu Arg Met Leu Glu Asp Asn Val Met Arg Pro Gly Tyr Tyr Gln 130 135 140	432
ctg cta caa gca tcc tta aca tgt tct ccc cac cgc cag cga cgc agc Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro His Arg Gln Arg Arg Ser 145 150 155 160	480

B09995A - SQL - eof-seq1

acc	aag	gac	aac	ttc	aat	gtc	tat	aaa	gcc	aca	aga	cca	tac	tta	gct	528
Thr	Lys	Asp	Asn	Phe	Asn	Val	Tyr	Lys	Ala	Thr	Arg	Pro	Tyr	Leu	Ala	
				165					170					175		
cac	tgt	ccc	gac	tgt	gga	gaa	ggg	cac	tcg	tgc	cat	agt	ccc	gta	gca	576
His	Cys	Pro	Asp	Cys	Gly	Glu	Gly	His	Ser	Cys	His	Ser	Pro	Val	Ala	
			180					185					190			
cta	gaa	cgc	atc	aga	aat	gaa	gcg	aca	gac	ggg	acg	ctg	aaa	atc	cag	624
Leu	Glu	Arg	Ile	Arg	Asn	Glu	Ala	Thr	Asp	Gly	Thr	Leu	Lys	Ile	Gln	
		195					200					205				
gtc	tcc	ttg	caa	atc	gga	ata	aag	acg	gat	gac	agc	cac	gat	tgg	acc	672
Val	Ser	Leu	Gln	Ile	Gly	Ile	Lys	Thr	Asp	Asp	Ser	His	Asp	Trp	Thr	
	210					215					220					
aag	ctg	cgt	tat	atg	gac	aac	cac	atg	cca	gca	gac	gca	gag	agg	gcg	720
Lys	Leu	Arg	Tyr	Met	Asp	Asn	His	Met	Pro	Ala	Asp	Ala	Glu	Arg	Ala	
225					230					235					240	
ggg	cta	ttt	gta	aga	aca	tca	gca	ccg	tgt	acg	att	act	gga	aca	atg	768
Gly	Leu	Phe	Val	Arg	Thr	Ser	Ala	Pro	Cys	Thr	Ile	Thr	Gly	Thr	Met	
				245					250					255		
gga	cac	ttc	atc	ctg	gcc	cga	tgt	cca	aaa	ggg	gaa	act	ctg	acg	gtg	816
Gly	His	Phe	Ile	Leu	Ala	Arg	Cys	Pro	Lys	Gly	Glu	Thr	Leu	Thr	Val	
			260					265					270			
gga	ttc	act	gac	agt	agg	aag	att	agt	cac	tca	tgt	acg	cac	cca	ttt	864
Gly	Phe	Thr	Asp	Ser	Arg	Lys	Ile	Ser	His	Ser	Cys	Thr	His	Pro	Phe	
		275					280					285				
cac	cac	gac	cct	cct	gtg	ata	ggg	cgg	gaa	aaa	ttc	cat	tcc	cga	ccg	912
His	His	Asp	Pro	Pro	Val	Ile	Gly	Arg	Glu	Lys	Phe	His	Ser	Arg	Pro	
	290					295					300					
cag	cac	ggg	aaa	gag	cta	cct	tgc	agc	acg	tac	gtg	cag	agc	acc	gcc	960
Gln	His	Gly	Lys	Glu	Leu	Pro	Cys	Ser	Thr	Tyr	Val	Gln	Ser	Thr	Ala	
305					310					315					320	
gca	act	acc	gag	gag	ata	gag	gta	cac	atg	ccc	cca	gac	acc	cct	gat	1008
Ala	Thr	Thr	Glu	Glu	Ile	Glu	Val	His	Met	Pro	Pro	Asp	Thr	Pro	Asp	
				325					330					335		
cgc	aca	tta	atg	tca	caa	cag	tcc	ggc	aac	gta	aag	atc	aca	gtc	aat	1056
Arg	Thr	Leu	Met	Ser	Gln	Gln	Ser	Gly	Asn	Val	Lys	Ile	Thr	Val	Asn	
			340					345					350			
ggc	cag	acg	gtg	cgg	tac	aag	tgt	aat	tgc	ggg	ggc	tca	aat	gaa	gga	1104
Gly	Gln	Thr	Val	Arg	Tyr	Lys	Cys	Asn	Cys	Gly	Gly	Ser	Asn	Glu	Gly	
		355					360					365				
cta	aca	act	aca	gac	aaa	gtg	att	aat	aac	tgc	aag	gtt	gat	caa	tgt	1152
Leu	Thr	Thr	Thr	Asp	Lys	Val	Ile	Asn	Asn	Cys	Lys	Val	Asp	Gln	Cys	
						375					380					
cat	gcc	gcg	gtc	acc	aat	cac	aaa	aag	tgg	cag	tat	aac	tcc	cct	ctg	1200
His	Ala	Ala	Val	Thr	Asn	His	Lys	Lys	Trp	Gln	Tyr	Asn	Ser	Pro	Leu	
385					390					395					400	
gtc	ccg	cgt	aat	gct	gaa	ctt	ggg	gac	cga	aaa	gga	aaa	att	cac	atc	1248
Val	Pro	Arg	Asn	Ala	Glu	Leu	Gly	Asp	Arg	Lys	Gly	Lys	Ile	His	Ile	
				405					410					415		

B09995A - SQL - eolf-seq1

ccg ttt ccg ctg gca aat gta aca tgc agg gtg cct aaa gca agg aac	1296
Pro Phe Pro Leu Ala Asn Val Thr Cys Arg Val Pro Lys Ala Arg Asn	
420 425 430	
ccc acc gtg acg tac ggg aaa aac caa gtc atc atg cta ctg tat cct	1344
Pro Thr Val Thr Tyr Gly Lys Asn Gln Val Ile Met Leu Leu Tyr Pro	
435 440 445	
gac cac cca aca ctc ctg tcc tac cgg aat atg gga gaa gaa cca aac	1392
Asp His Pro Thr Leu Leu Ser Tyr Arg Asn Met Gly Glu Glu Pro Asn	
450 455 460	
tat caa gaa gag tgg gtg atg cat aag aag gaa gtc gtg cta acc gtg	1440
Tyr Gln Glu Glu Trp Val Met His Lys Lys Glu Val Val Leu Thr Val	
465 470 475 480	
ccg act gaa ggg ctc gag gtc acg tgg ggc aac aac gag ccg tat aag	1488
Pro Thr Glu Gly Leu Glu Val Thr Trp Gly Asn Asn Glu Pro Tyr Lys	
485 490 495	
tat tgg ccg cag tta tct aca aac ggt aca gcc cat ggc cac ccg cac	1536
Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr Ala His Gly His Pro His	
500 505 510	
gag ata att ctg tat tat tat gag ctg tac ccc act atg act gta gta	1584
Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro Thr Met Thr Val Val	
515 520 525	
gtt gtg tca gtg gcc acg ttc ata ctc ctg tcg atg gtg ggt atg gca	1632
Val Val Ser Val Ala Thr Phe Ile Leu Leu Ser Met Val Gly Met Ala	
530 535 540	
gcg ggg atg tgc atg tgt gca cga cgc aga tgc atc aca ccg tat gaa	1680
Ala Gly Met Cys Met Cys Ala Arg Arg Arg Cys Ile Thr Pro Tyr Glu	
545 550 555 560	
ctg aca cca gga gct acc gtc cct ttc ctg ctt agc cta ata tgc tgc	1728
Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu Ser Leu Ile Cys Cys	
565 570 575	
atc aga aca gct aaa gcg gcc aca tac caa gag gct gcg ata tac ctg	1776
Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln Glu Ala Ala Ile Tyr Leu	
580 585 590	
tgg aac gag cag caa cct tta	1797
Trp Asn Glu Gln Gln Pro Leu	
595	

<210> 9
 <211> 599
 <212> PRT
 <213> Chikungunya virus

<400> 9

Ile Pro Val His Met Lys Ser Asp Ala Ser Lys Phe Thr His Glu Lys
1 5 10 15

Pro Glu Gly Tyr Tyr Asn Trp His His Gly Ala Val Gln Tyr Ser Gly
20 25 30

B09995A - SQL - eolf-seql

Gly Arg Phe Thr Ile Pro Thr Gly Ala Gly Lys Pro Gly Asp Ser Gly
35 40 45

Arg Pro Ile Phe Asp Asn Lys Gly Arg Val Val Ala Ile Val Leu Gly
50 55 60

Gly Ala Asn Glu Gly Ala Arg Thr Ala Leu Ser Val Val Thr Trp Asn
65 70 75 80

Lys Asp Ile Val Thr Lys Ile Thr Pro Glu Gly Ala Glu Glu Trp Ser
85 90 95

Leu Ala Ile Pro Val Met Cys Leu Leu Ala Asn Thr Thr Phe Pro Cys
100 105 110

Ser Gln Pro Pro Cys Thr Pro Cys Cys Tyr Glu Lys Glu Pro Glu Glu
115 120 125

Thr Leu Arg Met Leu Glu Asp Asn Val Met Arg Pro Gly Tyr Tyr Gln
130 135 140

Leu Leu Gln Ala Ser Leu Thr Cys Ser Pro His Arg Gln Arg Arg Ser
145 150 155 160

Thr Lys Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu Ala
165 170 175

His Cys Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Val Ala
180 185 190

Leu Glu Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile Gln
195 200 205

Val Ser Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp Thr
210 215 220

Lys Leu Arg Tyr Met Asp Asn His Met Pro Ala Asp Ala Glu Arg Ala
225 230 235 240

Gly Leu Phe Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr Met
245 250 255

Gly His Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr Val
260 265 270

Gly Phe Thr Asp Ser Arg Lys Ile Ser His Ser Cys Thr His Pro Phe
Page 30

06/27/2018 10:03 00436

275 B09995A - SQL - eolf-seq1 285
 280
 His His Asp Pro Pro Val Ile Gly Arg Glu Lys Phe His Ser Arg Pro
 290 295 300
 Gln His Gly Lys Glu Leu Pro Cys Ser Thr Tyr Val Gln Ser Thr Ala
 305 310 315 320
 Ala Thr Thr Glu Glu Ile Glu Val His Met Pro Pro Asp Thr Pro Asp
 325 330 335
 Arg Thr Leu Met Ser Gln Gln Ser Gly Asn Val Lys Ile Thr Val Asn
 340 345 350
 Gly Gln Thr Val Arg Tyr Lys Cys Asn Cys Gly Gly Ser Asn Glu Gly
 355 360 365
 Leu Thr Thr Thr Asp Lys Val Ile Asn Asn Cys Lys Val Asp Gln Cys
 370 375 380
 His Ala Ala Val Thr Asn His Lys Lys Trp Gln Tyr Asn Ser Pro Leu
 385 390 395 400
 Val Pro Arg Asn Ala Glu Leu Gly Asp Arg Lys Gly Lys Ile His Ile
 405 410 415
 Pro Phe Pro Leu Ala Asn Val Thr Cys Arg Val Pro Lys Ala Arg Asn
 420 425 430
 Pro Thr Val Thr Tyr Gly Lys Asn Gln Val Ile Met Leu Leu Tyr Pro
 435 440 445
 Asp His Pro Thr Leu Leu Ser Tyr Arg Asn Met Gly Glu Glu Pro Asn
 450 455 460
 Tyr Gln Glu Glu Trp Val Met His Lys Lys Glu Val Val Leu Thr Val
 465 470 475 480
 Pro Thr Glu Gly Leu Glu Val Thr Trp Gly Asn Asn Glu Pro Tyr Lys
 485 490 495
 Tyr Trp Pro Gln Leu Ser Thr Asn Gly Thr Ala His Gly His Pro His
 500 505 510
 Glu Ile Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro Thr Met Thr Val Val
 515 520 525

Val Val Ser Val Ala Thr Phe Ile Leu Leu Ser Met Val Gly Met Ala
530 535 540

Ala Gly Met Cys Met Cys Ala Arg Arg Arg Cys Ile Thr Pro Tyr Glu
545 550 555 560

Leu Thr Pro Gly Ala Thr Val Pro Phe Leu Leu Ser Leu Ile Cys Cys
565 570 575

Ile Arg Thr Ala Lys Ala Ala Thr Tyr Gln Glu Ala Ala Ile Tyr Leu
580 585 590

Trp Asn Glu Gln Gln Pro Leu
595

```
<210> 10
<211> 1092
<212> DNA
<213> Chikungunya virus
```

```
<220>
<221> misc_feature
<223> ectodomain glycoprotein E2 strain 05.115
```

```
<220>
<221> CDS
<222> (1)..(1092)
```

<400> 10 48
gac aac ttc aat gtc tat aaa gcc aca aga cca tac tta gct cac tgt
Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu Ala His Cys
1 5 10 15

ccc gac tgt gga gaa ggg cac tcg tgc cat agt ccc gta gca cta gaa 96
Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Val Ala Leu Glu
20 25 30

cgc atc aga aat gaa gcg aca gac ggg acg ctg aaa atc cag gtc tcc 144
 Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile Gln Val Ser
 35 40 45

ttg caa atc gga ata aag acg gat gac agc cac gat tgg acc aag ctg 192
Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp Thr Lys Leu
50 55 60

cgt tat atg gac aac cac atg cca gca gac gca gag agg gcg ggg cta 240
Arg Tyr Met Asp Asn His Met Pro Ala Asp Ala Glu Arg Ala Gly Leu
65 70 75 80

ttt gta aga aca tca gca ccg tgt acg att act gga aca atg gga cac 288
Phe Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr Met Gly His
85 90 95

ttc atc ctg gcc cga tgt cca aaa ggg gaa act ctg acg gtg gga ttc 336
Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr Val Gly Phe
100 105 110

06/27/2018 10:03 00438

B09995A - SQL - eof-seq1																	
act	gac	agt	agg	aag	att	agt	cac	tca	tgt	acg	cac	cca	ttt	cac	cac	384	
Thr	Asp	Ser	Arg	Lys	Ile	Ser	His	Ser	Cys	Thr	His	Pro	Phe	His	His		
		115					120					125					
gac	cct	cct	gtg	ata	ggg	cgg	gaa	aaa	ttc	cat	tcc	cga	ccg	cag	cac	432	
Asp	Pro	Pro	Val	Ile	Gly	Arg	Glu	Lys	Phe	His	Ser	Arg	Pro	Gln	His		
	130					135					140						
ggg	aaa	gag	ata	cct	tgc	agc	acg	tac	gtg	cag	agc	acc	gcc	gca	act	480	
Gly	Lys	Glu	Ile	Pro	Cys	Ser	Thr	Tyr	Val	Gln	Ser	Thr	Ala	Ala	Thr		
	145				150					155					160		
acc	gag	gag	ata	gag	gta	cac	atg	ccc	cca	gac	acc	cct	gat	cgc	aca	528	
Thr	Glu	Glu	Ile	Glu	Val	His	Met	Pro	Pro	Asp	Thr	Pro	Asp	Arg	Thr		
				165					170					175			
tta	atg	tca	caa	cag	tcc	ggc	aac	gta	aag	atc	aca	gtc	aat	ggc	cag	576	
Leu	Met	Ser	Gln	Gln	Ser	Gly	Asn	Val	Lys	Ile	Thr	Val	Asn	Gly	Gln		
			180					185					190				
acg	gtg	cgg	tac	aag	tgt	aat	tgc	ggg	ggc	tca	aat	gaa	gga	cta	aca	624	
Thr	Val	Arg	Tyr	Lys	Cys	Asn	Cys	Gly	Gly	Ser	Asn	Glu	Gly	Leu	Thr		
		195					200					205					
act	aca	gac	aaa	gtg	att	aat	aac	tgc	aag	gtt	gat	caa	tgt	cat	gcc	672	
Thr	Thr	Asp	Lys	Val	Ile	Asn	Asn	Cys	Lys	Val	Asp	Gln	Cys	His	Ala		
	210					215					220						
gcg	gtc	acc	aat	cac	aaa	aag	tgg	cag	tat	aac	tcc	cct	ctg	gtc	ccg	720	
Ala	Val	Thr	Asn	His	Lys	Lys	Trp	Gln	Tyr	Asn	Ser	Pro	Leu	Val	Pro		
	225				230					235					240		
cgt	aat	gct	gaa	ctt	ggg	gac	cga	aaa	gga	aaa	att	cac	atc	ccg	ttt	768	
Arg	Asn	Ala	Glu	Leu	Gly	Asp	Arg	Lys	Gly	Lys	Ile	His	Ile	Pro	Phe		
				245					250					255			
ccg	ctg	gca	aat	gta	aca	tgc	agg	gtg	cct	aaa	gca	agg	aac	ccc	acc	816	
Pro	Leu	Ala	Asn	Val	Thr	Cys	Arg	Val	Pro	Lys	Ala	Arg	Asn	Pro	Thr		
			260					265					270				
gtg	acg	tac	ggg	aaa	aac	caa	gtc	atc	atg	cta	ctg	tat	cct	gac	cac	864	
Val	Thr	Tyr	Gly	Lys	Asn	Gln	Val	Ile	Met	Leu	Leu	Tyr	Pro	Asp	His		
		275					280					285					
cca	aca	ctc	ctg	tcc	tac	cgg	aat	atg	gga	gaa	gaa	cca	aac	tat	caa	912	
Pro	Thr	Leu	Leu	Ser	Tyr	Arg	Asn	Met	Gly	Glu	Glu	Pro	Asn	Tyr	Gln		
	290					295					300						
gaa	gag	tgg	gtg	atg	cat	aag	aag	gaa	gtc	gtg	cta	acc	gtg	ccg	act	960	
Glu	Glu	Trp	Val	Met	His	Lys	Lys	Glu	Val	Val	Leu	Thr	Val	Pro	Thr		
	305				310					315					320		
gaa	ggg	ctc	gag	gtc	acg	tgg	ggc	aac	aac	gag	ccg	tat	aag	tat	tgg	1008	
Glu	Gly	Leu	Glu	Val	Thr	Trp	Gly	Asn	Asn	Glu	Pro	Tyr	Lys	Tyr	Trp		
				325					330					335			
ccg	cag	tta	tct	aca	aac	ggg	aca	gcc	cat	ggc	cac	ccg	cat	gag	ata	1056	
Pro	Gln	Leu	Ser	Thr	Asn	Gly	Thr	Ala	His	Gly	His	Pro	His	Glu	Ile		
			340					345					350				
att	ctg	tat	tat	tat	gag	ctg	tac	ccc	act	atg	act					1092	
Ile	Leu	Tyr	Tyr	Tyr	Glu	Leu	Tyr	Pro	Thr	Met	Thr						
		355					360										

<210> 11
 <211> 364
 <212> PRT
 <213> Chikungunya virus

<400> 11

Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu Ala His Cys
 1 5 10 15

Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Val Ala Leu Glu
 20 25 30

Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile Gln Val Ser
 35 40 45

Leu Gln Ile Gly Ile Lys Thr Asp Asp Ser His Asp Trp Thr Lys Leu
 50 55 60

Arg Tyr Met Asp Asn His Met Pro Ala Asp Ala Glu Arg Ala Gly Leu
 65 70 75 80

Phe Val Arg Thr Ser Ala Pro Cys Thr Ile Thr Gly Thr Met Gly His
 85 90 95

Phe Ile Leu Ala Arg Cys Pro Lys Gly Glu Thr Leu Thr Val Gly Phe
 100 105 110

Thr Asp Ser Arg Lys Ile Ser His Ser Cys Thr His Pro Phe His His
 115 120 125

Asp Pro Pro Val Ile Gly Arg Glu Lys Phe His Ser Arg Pro Gln His
 130 135 140

Gly Lys Glu Ile Pro Cys Ser Thr Tyr Val Gln Ser Thr Ala Ala Thr
 145 150 155 160

Thr Glu Glu Ile Glu Val His Met Pro Pro Asp Thr Pro Asp Arg Thr
 165 170 175

Leu Met Ser Gln Gln Ser Gly Asn Val Lys Ile Thr Val Asn Gly Gln
 180 185 190

Thr Val Arg Tyr Lys Cys Asn Cys Gly Gly Ser Asn Glu Gly Leu Thr
 195 200 205

Thr Thr Asp Lys Val Ile Asn Asn Cys Lys Val Asp Gln Cys His Ala
 210 215 220

Ala Val Thr Asn His Lys Lys Trp Gln Tyr Asn Ser Pro Leu Val Pro
225 230 235 240

Arg Asn Ala Glu Leu Gly Asp Arg Lys Gly Lys Ile His Ile Pro Phe
245 250 255

Pro Leu Ala Asn Val Thr Cys Arg Val Pro Lys Ala Arg Asn Pro Thr
260 265 270

Val Thr Tyr Gly Lys Asn Gln Val Ile Met Leu Leu Tyr Pro Asp His
275 280 285

Pro Thr Leu Leu Ser Tyr Arg Asn Met Gly Glu Glu Pro Asn Tyr Gln
290 295 300

Glu Glu Trp Val Met His Lys Lys Glu Val Val Leu Thr Val Pro Thr
305 310 315 320

Glu Gly Leu Glu Val Thr Trp Gly Asn Asn Glu Pro Tyr Lys Tyr Trp
325 330 335

Pro Gln Leu Ser Thr Asn Gly Thr Ala His Gly His Pro His Glu Ile
340 345 350

Ile Leu Tyr Tyr Tyr Glu Leu Tyr Pro Thr Met Thr
355 360

<210> 12
<211> 1092
<212> DNA
<213> Chikungunya virus

<220>
<221> misc_feature
<223> ectodomain glycoprotein E2 strain 06.21

<220>
<221> CDS
<222> (1)..(1092)

<400> 12
gac aac ttc aat gtc tat aaa gcc aca aga cca tac tta gct cac tgt 48
Asp Asn Phe Asn Val Tyr Lys Ala Thr Arg Pro Tyr Leu Ala His Cys
1 5 10 15

ccc gac tgt gga gaa ggg cac tcg tgc cat agt ccc gta gca cta gaa 96
Pro Asp Cys Gly Glu Gly His Ser Cys His Ser Pro Val Ala Leu Glu
20 25 30

cgc atc aga aat gaa gcg aca gac ggg acg ctg aaa atc cag gtc tcc 144
Arg Ile Arg Asn Glu Ala Thr Asp Gly Thr Leu Lys Ile Gln Val Ser
Page 35

B09995A - SQL - eolf-seql																
35				40				45								
ttg	caa	atc	gga	ata	aag	acg	gat	gac	agc	cac	gat	tgg	acc	aag	ctg	192
Leu	Gln	Ile	Gly	Ile	Lys	Thr	Asp	Asp	Ser	His	Asp	Trp	Thr	Lys	Leu	
	50					55					60					
cgt	tat	atg	gac	aac	cac	atg	cca	gca	gac	gca	gag	agg	gcg	ggg	cta	240
Arg	Tyr	Met	Asp	Asn	His	Met	Pro	Ala	Asp	Ala	Glu	Arg	Ala	Gly	Leu	
65					70					75					80	
ttt	gta	aga	aca	tca	gca	ccg	tgt	acg	att	act	gga	aca	atg	gga	cac	288
Phe	Val	Arg	Thr	Ser	Ala	Pro	Cys	Thr	Ile	Thr	Gly	Thr	Met	Gly	His	
				85					90					95		
ttc	atc	ctg	gcc	cga	tgt	cca	aaa	ggg	gaa	act	ctg	acg	gtg	gga	ttc	336
Phe	Ile	Leu	Ala	Arg	Cys	Pro	Lys	Gly	Glu	Thr	Leu	Thr	Val	Gly	Phe	
			100					105					110			
act	gac	agt	agg	aag	att	agt	cac	tca	tgt	acg	cac	cca	ttt	cac	cac	384
Thr	Asp	Ser	Arg	Lys	Ile	Ser	His	Ser	Cys	Thr	His	Pro	Phe	His	His	
		115					120					125				
gac	cct	cct	gtg	ata	ggg	cgg	gaa	aaa	ttc	cat	tcc	cga	ccg	cag	cac	432
Asp	Pro	Pro	Val	Ile	Gly	Arg	Glu	Lys	Phe	His	Ser	Arg	Pro	Gln	His	
	130					135					140					
ggg	aaa	gag	cta	cct	tgc	agc	acg	tac	gtg	cag	agc	acc	gcc	gca	act	480
Gly	Lys	Glu	Leu	Pro	Cys	Ser	Thr	Tyr	Val	Gln	Ser	Thr	Ala	Ala	Thr	
145					150					155					160	
acc	gag	gag	ata	gag	gta	cac	atg	ccc	cca	gac	acc	cct	gat	cg	aca	528
Thr	Glu	Glu	Ile	Glu	Val	His	Met	Pro	Pro	Asp	Thr	Pro	Asp	Arg	Thr	
				165					170					175		
tta	atg	tca	caa	cag	tcc	ggc	aac	gta	aag	atc	aca	gtc	aat	ggc	cag	576
Leu	Met	Ser	Gln	Gln	Ser	Gly	Asn	Val	Lys	Ile	Thr	Val	Asn	Gly	Gln	
			180					185					190			
acg	gtg	cgg	tac	aag	tgt	aat	tgc	ggg	ggc	tca	aat	gaa	gga	cta	aca	624
Thr	Val	Arg	Tyr	Lys	Cys	Asn	Cys	Gly	Gly	Ser	Asn	Glu	Gly	Leu	Thr	
		195					200					205				
act	aca	gac	aaa	gtg	att	aat	aac	tgc	aag	gtt	gat	caa	tgt	cat	gcc	672
Thr	Thr	Asp	Lys	Val	Ile	Asn	Asn	Cys	Lys	Val	Asp	Gln	Cys	His	Ala	
	210					215					220					
gcg	gtc	acc	aat	cac	aaa	aag	tgg	cag	tat	aac	tcc	cct	ctg	gtc	ccg	720
Ala	Val	Thr	Asn	His	Lys	Lys	Trp	Gln	Tyr	Asn	Ser	Pro	Leu	Val	Pro	
225					230					235					240	
cgt	aat	gct	gaa	ctt	ggg	gac	cga	aaa	gga	aaa	att	cac	atc	ccg	ttt	768
Arg	Asn	Ala	Glu	Leu	Gly	Asp	Arg	Lys	Gly	Lys	Ile	His	Ile	Pro	Phe	
				245					250					255		
ccg	ctg	gca	aat	gta	aca	tgc	agg	gtg	cct	aaa	gca	agg	aac	ccc	acc	816
Pro	Leu	Ala	Asn	Val	Thr	Cys	Arg	Val	Pro	Lys	Ala	Arg	Asn	Pro	Thr	
			260					265					270			
gtg	acg	tac	ggg	aaa	aac	caa	gtc	atc	atg	cta	ctg	tat	cct	gac	cac	864
Val	Thr	Tyr	Gly	Lys	Asn	Gln	Val	Ile	Met	Leu	Leu	Tyr	Pro	Asp	His	
		275					280					285				
cca	aca	ctc	ctg	tcc	tac	cgg	aat	atg	gga	gaa	gaa	cca	aac	tat	caa	912

CLAIMS

1. A nucleic acid construct which comprises:

- (1) a polynucleotide encoding the C-E3-E2-6K-E1 structural proteins of a Chikungunya virus (CHIKV); and
- (2) a cDNA molecule which encodes a full-length, infectious antigenomic (+) RNA strand of a measles virus (MV);

wherein the polynucleotide encoding the C-E3-E2-6K-E1 structural proteins and the cDNA molecule are operatively linked.

2. The nucleic acid construct according to claim 1, wherein said cDNA molecule consists of a number of nucleotides that is a multiple of six.

3. The nucleic acid construct according to claim 1, comprising the following polynucleotides from 5' to 3':

- (a) a polynucleotide encoding a full length of N protein of the MV,
- (b) a polynucleotide encoding a full length of P protein of the MV,
- (c) the polynucleotide encoding the C-E3-E2-6K-E1 structural proteins of CHIKV,
- (d) a polynucleotide encoding a full length of M protein of the MV,
- (e) a polynucleotide encoding a full length of F protein of the MV,
- (f) a polynucleotide encoding a full length of H protein of the MV, and
- (g) a polynucleotide encoding a full length of L protein of the MV,

wherein said polynucleotides are operably linked in the nucleic acid construct and under a control of viral replication and transcription regulatory sequences.

2018 JUN -4 PM 4:15
 RECEIVED
 U.S. PATENT & TRADEMARK OFFICE

4. The nucleic acid construct according to claim 1, wherein said Measles virus is an attenuated virus strain selected from the group consisting of the Schwarz strain, the Zagreb strain, the AIK-C strain and the Moraten strain.
5. The nucleic acid construct according to claim 1, wherein said polynucleotide encoding the C-E3-E2-6K-E1 structural proteins of CHIKV has been optimized for a Macacca codon usage or has been optimized for a human codon usage.
6. The nucleic acid construct according to claim 1, wherein said polynucleotide encoding the C-E3-E2-6K-E1 structural proteins comprises at least one measles editing-like sequence selected from AAAGGG, AAAAGG, GGGAAA, and GGGGAA that has been mutated.
7. The nucleic acid construct according to claim 1, wherein said Chikungunya virus is from the strain designated 06-49 strain.
8. The nucleic acid construct according to claim 1, wherein the encoded E2 structural protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 11, SEQ ID NO: 13, and SEQ ID NO: 15.
9. The nucleic acid construct according to claim 1, wherein said nucleic acid construct encodes C-E3-E2-6K-E1 structural proteins having a sequence selected from

the group consisting of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26 and SEQ ID NO: 28.

10. The nucleic acid construct according to claim 1, wherein said nucleic acid construct comprises a sequence selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 27, and SEQ ID NO: 31.

11. A transfer vector plasmid, comprising the nucleic acid construct of claim 1.

12. The vector according to claim 11, wherein said vector is pMV-CHIKV.

13. Transformed eukaryotic cells comprising the nucleic acid construct according to claim 1.

14. Recombinant infectious replicating MV-CHIKV particles produced by a method comprising expressing the nucleic acid construct according to claim 1 in a host cell comprising an RNA polymerase recognized by said host cell, a nucleoprotein (N) of a MV, and a phosphoprotein (P) of a MV.

15. The recombinant infectious replicating MV-CHIKV particles of claim 14, wherein said virus particles are encoded by a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO: 27 and SEQ ID NO: 31.

16. A composition comprising the recombinant infectious replicating MV-CHIKV particles according to claim 14, CHIKV-C-E3-E2-6K-E1 Virus Like Particles (VLPs) and a pharmaceutically acceptable vehicle.

17. Use of the composition according to claim 16 for the manufacture of a vaccine in the elicitation of a protective immune response against CHIKV in a host.

18. Use of the composition according to claim 16 in the manufacture of a medicament for the treatment or the prevention of an infection by CHIKV in a host.

19. A process to rescue recombinant measles virus (MV) expressing the C-E3-E2-6K-E1 structural proteins of a Chikungunya virus (CHIKV) and CHIKV-C-E3-E2-6K-E1 Virus Like Particles (VLPs), comprising:

1) cotransfecting helper cells that stably express T7 RNA polymerase, and measles N and P proteins with (i) a transfer vector plasmid according to claim 11, and (ii) a vector, encoding the MV L polymerase;

2) cultivating said cotransfected helper cells in conditions enabling the production of MV-CHIKV recombinant virus;

3) propagating the thus produced recombinant virus by co-cultivating said helper cells of step 2) with cells enabling said propagation; and

4) recovering replicating MV-CHIKV recombinant virus expressing the C-E3-E2-6K-E1 structural proteins of CHIKV and CHIKV-C-E3-E2-6K-E1 VLPs.

20. The process according to claim 19, wherein the transfer vector plasmid comprises a sequence selected from the group consisting of SEQ ID NO: 27 and SEQ ID NO: 31.






FIGURE 1A

3 constructions :

- 1 - MV-CE3E26KE1
- 2 - MV-sE2
- 3 - MV-sE2 Δ stem



Travis Anne Taur
 LESLIE ANNE T. CRUZ
 CESAR C. CRUZ & PARTNERS
 Resident Agent

CENTRE NATIONAL DE LA RECHERCHE
 SCIENTIFIQUE: INSTITUT PASTEUR and IHEMIS
 BIOSCIENCE
 Applicant

2018 JUN -14 PM 4:16

RECEIVED IN
 NATIONAL PROPERTY OFFICE

Rescue of recombinant MV expressing CHIKV VLP




FIGURE 1B

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE; INSTITUT PASTEUR and THEMIS
BIOSCIENCE
Applicant

by:

Leslie Anne T. Cruz
LESLIE ANNE T. CRUZ
CESAR C. CRUZ & PARTNERS
Resident Agent




FIGURE 2




FIGURE 3

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE; INSTITUT PASTEUR and THEMIS

BIOSCIENCE

Applicant

by:

Leslie Anne T. Cruz
LESLIE ANNE T. CRUZ
CESAR C. CRUZ & PARTNERS
Resident Agent




FIGURE 4

SLAIPVMCLLANTTFPCSOENHVVYVTPYLAHEDCEGHSCHEVA
 ENIRNEALDCTLKQVSLQPCIKTHSHOVTKIRYMDHNPADAEXBUL
 VRTSAPCTITCTMCEHILARHIGDTHVGEIDSKISHSCHEFHNDZ
 VIGRE

FIGURE 5




FIGURE 6

CENTRE NATIONAL DE LA RECHERCHE
 SCIENTIFIQUE; INSTITUT PASTEUR and THEMIS
 BIOSCIENCE
 Applicant

by:

Leslie Anne T. Cruz
 LESLIE ANNE T. CRUZ
 CESAR C. CRUZ & PARTNERS
 Resident Agent




FIGURE 7




FIGURE 8

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE; INSTITUT PASTEUR and THEMIS
BIOSCIENCE
Applicant

by:

Leslie Anne T. Cruz
LESLIE ANNE T. CRUZ
CESAR C. CRUZ & PARTNERS
Resident Agent

6/11




FIGURE 9




FIGURE 10

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE; INSTITUT PASTEUR and THEMIS
BIOSCIENCE
Applicant

by:

Leslie Anne T. Cruz
LESLIE ANNE T. CRUZ
CESAR C. CRUZ & PARTNERS
Resident Agent

7/11




FIGURE 11




FIGURE 12

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE; INSTITUT PASTEUR and THEMIS
BIOSCIENCE
Applicant

by:

Leslie Anne T. Cruz
LESLIE ANNE T. CRUZ
CESAR C. CRUZ & PARTNERS
Resident Agent




FIGURE 13




FIGURE 14

CENTRE NATIONAL DE LA RECHERCHE
 SCIENTIFIQUE, INSTITUT PASTEUR and THEMIS
 BIOSCIENCE
 Applicant

by:

Leslie Anne T. Cruz
 LESLIE ANNE T. CRUZ
 CESAR C. CRUZ & PARTNERS
 Resident Agent

9/11




FIGURE 15

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE; INSTITUT PASTEUR and THEMIS
BIOSCIENCE
Applicant

by:

Leslie Anne Cruz
LESLIE ANNE T. CRUZ
CESAR C. CRUZ & PARTNERS
Resident Agent




FIGURE 16




FIGURE 17

CENTRE NATIONAL DE LA RECHERCHE
SCIENTIFIQUE; INSTITUT PASTEUR and THEMIS
BIOSCIENCE
Applicant

by:

Leslie Anne T. Cruz
LESLIE ANNE T. CRUZ
CESAR C. CRUZ & PARTNERS
Resident Agent

2018 JUN -4 PM 4:16
 RECEIVED
 INTERNATIONAL PROPERTY OFFICE




FIGURE 18

CENTRE NATIONAL DE LA RECHERCHE
 SCIENTIFIQUE; INSTITUT PASTEUR and THEMIS
 BIOSCIENCE
 Applicant

by:

Leslie Anne T. Cruz
 LESLIE ANNE T. CRUZ
 CESAR C. CRUZ & PARTNERS
 Resident Agent